<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-2651 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-2651</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-2651</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-68.html">extraction-schema-68</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <p><strong>Paper ID:</strong> paper-836e965cd93369089027d31d92a55b5819cae267</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/836e965cd93369089027d31d92a55b5819cae267" target="_blank">Network medicine framework for identifying drug-repurposing opportunities for COVID-19</a></p>
                <p><strong>Paper Venue:</strong> Proceedings of the National Academy of Sciences of the United States of America</p>
                <p><strong>Paper TL;DR:</strong> This work deployed algorithms relying on artificial intelligence, network diffusion, and network proximity to rank 6,340 drugs for their expected efficacy against SARS-CoV-2, finding that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines.</p>
                <p><strong>Paper Abstract:</strong> Significance The COVID-19 pandemic has highlighted the importance of prioritizing approved drugs to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. We experimentally screened 918 drugs, allowing us to evaluate the performance of the existing drug-repurposing methodologies, and used a consensus algorithm to increase the accuracy of the predictions. Finally, we screened in human cells the top-ranked drugs, identifying six drugs that reduced viral infection, four of which could be repurposed to treat COVID-19. The developed strategy has significance beyond COVID-19, allowing us to identify drug-repurposing candidates for neglected diseases. The COVID-19 pandemic has highlighted the need to quickly and reliably prioritize clinically approved compounds for their potential effectiveness for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs experimentally screened in VeroE6 cells, as well as the list of drugs in clinical trials that capture the medical communityâ€™s assessment of drugs with potential COVID-19 efficacy. We find that no single predictive algorithm offers consistently reliable outcomes across all datasets and metrics. This outcome prompted us to develop a multimodal technology that fuses the predictions of all algorithms, finding that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We screened in human cells the top-ranked drugs, obtaining a 62% success rate, in contrast to the 0.8% hit rate of nonguided screenings. Of the six drugs that reduced viral infection, four could be directly repurposed to treat COVID-19, proposing novel treatments for COVID-19. We also found that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these network drugs rely on network-based mechanisms that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.</p>
                <p><strong>Cost:</strong> 0.017</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e2651.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e2651.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>AI-based pipelines (A1-A4)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Artificial intelligence-based drug repurposing pipelines A1-A4</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A set of four AI-driven predictive pipelines that map drug protein targets and disease-associated proteins into a low-dimensional vector space (different drug-disease embeddings) to rank drugs by predicted efficacy against SARS-CoV-2.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>AI-based embedding pipelines (A1-A4)</td>
                        </tr>
                        <tr>
                            <td><strong>system_description</strong></td>
                            <td>Maps drug protein targets and disease-associated proteins to points in a low-dimensional vector space (multiple embedding variants) and produces ranked lists of candidate drugs; implemented as four predictive pipelines (A1-A4) that rely on different drug-disease embeddings. The implementation in this paper treats each pipeline as a distinct embedding-based predictor and produces frozen ranked outputs (predictions saved as of 2020-04-15). The paper does not provide detailed architecture (e.g., exact embedding algorithm or neural network architecture) in the main text; it characterizes them as artificial intelligence / embedding-based methods producing drug-disease similarity scores and rankings.</td>
                        </tr>
                        <tr>
                            <td><strong>system_type</strong></td>
                            <td>graph-embedding / embedding-based (AI)</td>
                        </tr>
                        <tr>
                            <td><strong>scientific_domain</strong></td>
                            <td>biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_generation_method</strong></td>
                            <td>Generates hypotheses by ranking drugs according to similarity / proximity in the embedding space between drug targets and disease-associated proteins; top-ranked drugs constitute hypotheses of potential efficacy against SARS-CoV-2.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_assessment_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>plausibility_assessment_method</strong></td>
                            <td>Implicit plausibility comes from proximity/similarity in learned embedding space and from downstream performance on ground-truth datasets (E918 experimental screen and CT415 clinical-trial list); no explicit internal plausibility scoring method beyond ranking is described in the main text.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_plausibility_balance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_quality_metrics</strong></td>
                            <td>Evaluated using standard ranking and classification metrics against ground truth: AUC (area under ROC), precision@K (number of positives among top K ranked drugs), recall@K (fraction of all positives appearing in top K). Specific reported values: AI pipelines achieved AUC=0.73-0.76 on CT415 (clinical-trial dataset), and various precision/recall results shown in figures.</td>
                        </tr>
                        <tr>
                            <td><strong>pre_experiment_evaluation</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_mechanism</strong></td>
                            <td>Computational ranking validated prospectively against two ground-truth datasets: (1) experimental in vitro screen of 918 drugs in VeroE6 cells (E918), classifying drugs Strong/Weak/No-effect/Cytotoxic; (2) a snapshot of drugs in clinical trials on 2020-04-15 (CT415). Performance metrics (AUC, precision/recall) quantify predictive performance prior to experimental follow-up.</td>
                        </tr>
                        <tr>
                            <td><strong>reproducibility_measures</strong></td>
                            <td>Predictions for all pipelines were produced using the same input data and frozen on a specific date (predictions saved on April 15, 2020) to maintain a prospective evaluation; the paper reports the exact drug lists and uses the same held-out experimental datasets (E918) for evaluation.</td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_prevention_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>statistical_significance_testing</strong></td>
                            <td>Authors report statistically significant predictive power across methods (see SI Section 3.1 and Tables S1-2), but the main text does not enumerate the specific statistical tests; details are referenced in the Supplementary Information.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>benchmark_dataset</strong></td>
                            <td>E918 (experimental in vitro VeroE6 screen of 918 drugs), CT415 (clinical trials snapshot on 2020-04-15), additionally E74 (expert-curated prospective list) and CT615 (clinical trials refreshed on 2020-06-15) used elsewhere in SI.</td>
                        </tr>
                        <tr>
                            <td><strong>performance_metrics</strong></td>
                            <td>On CT415 (clinical-trial snapshot) AI pipelines achieved AUC in the range 0.73-0.76. For the experimental E918 dataset AI pipelines had lower AUCs (specific pipelines varied); precision@100 and recall@100 reported in figures (examples: A2 ranks 9 S&W drugs among top 100 in E918; A1 ranks 12 CT415 drugs among top 100). Exact numeric precision/recall curves are shown in Figure 4.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_baseline</strong></td>
                            <td>AI pipelines outperformed proximity methods on the CT415 clinical-trial dataset (AI AUC 0.73-0.76 vs proximity P1 AUC=0.57), but did not uniformly outperform other methods on the experimental E918 dataset; performance was dataset-dependent.</td>
                        </tr>
                        <tr>
                            <td><strong>validated_on_real_science</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>novel_discoveries</strong></td>
                            <td>AI pipelines contributed to ranking drugs that later appeared in clinical trials and that matched experimental hits; specific top-ranked drugs by AI pipelines are included in the CRank consensus and experimental validation outcomes (see Tables).</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>The AI pipelines' predictive power is dataset-dependent (stronger for clinical-trial list than experimental in-vitro screen); main-text lacks low-level architectural detail of embeddings; no explicit internal uncertainty quantification or hallucination-detection mechanism described.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Network medicine framework for identifying drug-repurposing opportunities for COVID-19', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e2651.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e2651.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Diffusion pipelines (D1-D5)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Network diffusion-based drug repurposing pipelines D1-D5</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Five diffusion-inspired pipelines that use network diffusion / diffusion state distance concepts to capture network similarity between drug targets and SARS-CoV-2 host protein targets to rank drug candidates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Network diffusion pipelines (D1-D5)</td>
                        </tr>
                        <tr>
                            <td><strong>system_description</strong></td>
                            <td>Algorithms inspired by diffusion state distance: diffusion over the human protein-protein interaction network quantifies network similarity between drug target sets and SARS-CoV-2 host proteins; multiple pipelines (D1-D5) implement distinct statistical measures on diffusion-derived similarity scores to produce ranked drug lists.</td>
                        </tr>
                        <tr>
                            <td><strong>system_type</strong></td>
                            <td>network-diffusion / graph-signal-processing</td>
                        </tr>
                        <tr>
                            <td><strong>scientific_domain</strong></td>
                            <td>biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_generation_method</strong></td>
                            <td>Generates hypotheses by computing diffusion-based similarity/proximity between a drug's protein targets and the COVID-19 disease module in the interactome; drugs with high diffusion-based similarity are ranked highly as candidate therapeutics.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_assessment_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>plausibility_assessment_method</strong></td>
                            <td>Plausibility is inferred from network proximity/diffusion metrics and validated by subsequent comparison to experimental (E918) and clinical (CT415) datasets; no other explicit plausibility scoring described.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_plausibility_balance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_quality_metrics</strong></td>
                            <td>Same evaluation metrics as other pipelines: AUC, precision@K, recall@K. Reported example: D2 achieved AUC=0.58 on the E918 experimental dataset.</td>
                        </tr>
                        <tr>
                            <td><strong>pre_experiment_evaluation</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_mechanism</strong></td>
                            <td>Prospective validation against the E918 in vitro screen and CT415 clinical trial snapshot using AUC, precision and recall metrics.</td>
                        </tr>
                        <tr>
                            <td><strong>reproducibility_measures</strong></td>
                            <td>Predictions frozen on April 15, 2020 and sharing same input interactome/disease-target data across pipelines; specific diffusion algorithmic details and parameters are described in the Supplementary Information (Section 1.4.2).</td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_prevention_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>statistical_significance_testing</strong></td>
                            <td>Predictive power and statistical significance are reported (see SI Section 3.1) though exact test names are not enumerated in main text.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>benchmark_dataset</strong></td>
                            <td>E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot), additional datasets in SI.</td>
                        </tr>
                        <tr>
                            <td><strong>performance_metrics</strong></td>
                            <td>Example performance: D2 AUC = 0.58 on E918. Overall diffusion pipelines contributed to the set of predictions; different diffusion-based pipelines ranked different subsets of true positives.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_baseline</strong></td>
                            <td>Diffusion pipelines performed better than some methods for E918 (e.g., proximity performed well too), but did not uniformly outperform AI pipelines on CT415; methods are complementary (low correlation among pipeline rankings).</td>
                        </tr>
                        <tr>
                            <td><strong>validated_on_real_science</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>novel_discoveries</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Performance varies by ground-truth dataset; diffusion approaches capture network proximity but may miss non-network mechanisms; paper notes low correlation across different methods indicating complementary but inconsistent performance.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Network medicine framework for identifying drug-repurposing opportunities for COVID-19', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e2651.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e2651.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Proximity pipelines (P1-P3)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Network proximity-based drug repurposing pipelines P1-P3</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Three proximity-based pipelines that rank drugs by shortest-path or distance measures between drug target proteins and SARS-CoV-2 host protein targets in the human interactome, with variants excluding drug carriers/metabolizers or using drug-induced gene expression.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Proximity-based pipelines (P1-P3)</td>
                        </tr>
                        <tr>
                            <td><strong>system_description</strong></td>
                            <td>Compute network-based proximity between drug target proteins and the COVID-19 disease module in the interactome; produce three variants: P1 uses all drug targets, P2 ignores targets flagged as carriers/transporters/metabolizing enzymes, and P3 relies on differentially expressed genes after drug exposure in cultured cells.</td>
                        </tr>
                        <tr>
                            <td><strong>system_type</strong></td>
                            <td>network-proximity / graph-distance-based</td>
                        </tr>
                        <tr>
                            <td><strong>scientific_domain</strong></td>
                            <td>biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_generation_method</strong></td>
                            <td>Generates hypotheses by ranking drugs whose targets are closest (in network distance) to the SARS-CoV-2 host-target disease module; closer proximity implies higher potential efficacy.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_assessment_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>plausibility_assessment_method</strong></td>
                            <td>Plausibility inferred from network proximity Z-scores versus random expectation; the paper reports that targets of effective drugs are closer to the COVID-19 module than expected by chance.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_plausibility_balance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_quality_metrics</strong></td>
                            <td>AUC, precision@K, recall@K; example: P1 achieved AUC=0.63 on E918 (best single-pipeline AUC on the experimental dataset).</td>
                        </tr>
                        <tr>
                            <td><strong>pre_experiment_evaluation</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_mechanism</strong></td>
                            <td>Validated prospectively against E918 in vitro screening and CT415 clinical-trial snapshot; also network-based statistical comparisons to random expectation (proximity Z-scores).</td>
                        </tr>
                        <tr>
                            <td><strong>reproducibility_measures</strong></td>
                            <td>Predictions were computed using the same interactome and drug-target datasets and frozen on April 15, 2020; P3 predicts fewer drugs because it relies on drug-induced gene expression data.</td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_prevention_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>statistical_significance_testing</strong></td>
                            <td>Network proximity results are reported with Z-scores comparing to random expectation; broader statistical significance testing for predictive power referenced in SI (Section 3.1).</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>benchmark_dataset</strong></td>
                            <td>E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot).</td>
                        </tr>
                        <tr>
                            <td><strong>performance_metrics</strong></td>
                            <td>P1 AUC = 0.63 on E918 (best AUC on experimental dataset); P1 AUC = 0.57 on CT415, P2 AUC = 0.56 on CT415. Proximity measures (Z-scores) show S and W drug targets are significantly closer to COVID-19 module than N drugs (random expectation).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_baseline</strong></td>
                            <td>Proximity outperformed other methods on the experimental E918 dataset (P1 had highest single-pipeline AUC there), while AI pipelines performed better on the clinical-trial dataset; pipelines are complementary.</td>
                        </tr>
                        <tr>
                            <td><strong>validated_on_real_science</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>novel_discoveries</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>P3 predicts fewer drugs owing to requirement for drug-induced expression data; proximity methods capture network-neighborhood effects but may fail to capture other mechanisms; overall variable performance across datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Network medicine framework for identifying drug-repurposing opportunities for COVID-19', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e2651.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e2651.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>CRank</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>CRank rank aggregation algorithm (Bayesian factor-based Kemeny approximation)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An unsupervised rank aggregation algorithm that uses Bayesian factors to approximate a Kemeny consensus across multiple predictive pipelines, producing a consensus ranking that consistently matches or exceeds individual pipeline performance.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Prioritizing Network Communities</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>CRank (Bayesian rank aggregation)</td>
                        </tr>
                        <tr>
                            <td><strong>system_description</strong></td>
                            <td>CRank is a heuristic rank aggregation algorithm that approximates the Kemeny consensus by leveraging Bayesian factors to weigh and combine multiple ranking lists; it seeks a ranking that maximizes pairwise agreements among pipelines and produces a consensus ranking used to prioritize candidate drugs.</td>
                        </tr>
                        <tr>
                            <td><strong>system_type</strong></td>
                            <td>ensemble / Bayesian rank-aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>scientific_domain</strong></td>
                            <td>biology, medicine (drug repurposing; network medicine)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_generation_method</strong></td>
                            <td>Takes as input multiple hypothesis-producing pipelines (ranked drug lists) and produces an aggregated consensus ranking; hypotheses are the top-K drugs in the CRank consensus list.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_assessment_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>plausibility_assessment_method</strong></td>
                            <td>Plausibility is assessed empirically by measuring the consensus ranking's hit rate against experimental and clinical ground truth datasets; CRank's Bayesian weighting favors consensus among diverse pipelines, which empirically increases plausibility of top-ranked hypotheses.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_plausibility_balance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_quality_metrics</strong></td>
                            <td>Evaluated using AUC, precision@K, recall@K; CRank achieved consistently high precision/recall across datasets. Specific metrics: CRank top-100 hit rate ~9% (order-of-magnitude higher than brute-force baseline 0.8%); top-800 of 6,340 drugs prioritized by CRank contained 58 of the 77 S&W experimental hits.</td>
                        </tr>
                        <tr>
                            <td><strong>pre_experiment_evaluation</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_mechanism</strong></td>
                            <td>Consensus predictions validated prospectively against the E918 in vitro screen and CT415 clinical-trial snapshot, and also tested on an expert-curated E74 prospective list and CT615 (clinical trials updated 06/15/20); CRank matched or exceeded best individual pipelines across these datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>reproducibility_measures</strong></td>
                            <td>CRank aggregation was applied to the twelve frozen ranked lists (predictions frozen on 2020-04-15); experimental validation and manual curation steps are described and the aggregated ranked lists (top-100) are provided (Table 1), enabling reproducibility.</td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_prevention_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>statistical_significance_testing</strong></td>
                            <td>CRank's performance and significance reported across datasets (details in SI); the algorithm's success is justified empirically via comparisons of precision/recall and AUC versus individual pipelines and other aggregation heuristics.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification_method</strong></td>
                            <td>Uses Bayesian factors as part of the aggregation process; Bayesian factors serve to weight evidence from different pipelines and implicitly capture inter-pipeline support (a form of uncertainty-weighted aggregation).</td>
                        </tr>
                        <tr>
                            <td><strong>benchmark_dataset</strong></td>
                            <td>E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot 04/15/20), E74 (expert-curated), CT615 (06/15/20 refreshed clinical trials).</td>
                        </tr>
                        <tr>
                            <td><strong>performance_metrics</strong></td>
                            <td>CRank produced the best-consistent performance across datasets: top-100 hit rate ~9% (9 S&W drugs among CRank top-100); top-800 contained 58 of the 77 S&W drugs. CRank outperformed Average Rank and other simpler aggregation methods across most K values (Figure 4G-H).</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_baseline</strong></td>
                            <td>CRank outperformed Average Rank (which performed worst), outperformed Union list and Dowdall in many settings, and matched/exceeded the best individual pipelines across datasets; CRank yielded ~9% top-100 hit rate versus brute-force screening baseline of 0.8%.</td>
                        </tr>
                        <tr>
                            <td><strong>validated_on_real_science</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>novel_discoveries</strong></td>
                            <td>Using the CRank consensus and subsequent experimental screening, the study identified experimentally validated candidate drugs not widely in trials at the time (e.g., azelastine, digoxin) and highlighted several drugs with positive in vitro outcomes; these are presented as candidates for clinical consideration.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>CRank depends on the quality and diversity of input pipelines; it aggregates existing predictions but does not generate fundamentally new mechanistic models; Bayesian factor details and priors are not fully elaborated in main text (some details are in referenced literature).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Network medicine framework for identifying drug-repurposing opportunities for COVID-19', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e2651.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e2651.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of AI systems or methods that generate scientific hypotheses, evaluate hypothesis quality, validate scientific claims, detect hallucinations, or quantify uncertainty in scientific reasoning.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Rank aggregation heuristics (Average Rank, Borda, Dowdall, Union, Kemeny)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Rank aggregation heuristics: Average Rank, Borda count, Dowdall method, Union-of-top-k, and Kemeny consensus (theoretical)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A set of methods for combining multiple ranked lists into a single prioritized list: simple averaging of ranks, Borda count, the Dowdall method, selecting union of top-k lists, and the theoretical Kemeny consensus (NP-hard) as the optimal aggregation target.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>here</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>system_name</strong></td>
                            <td>Rank aggregation heuristics (Average Rank, Borda, Dowdall, Union, Kemeny)</td>
                        </tr>
                        <tr>
                            <td><strong>system_description</strong></td>
                            <td>Algorithms to aggregate multiple ranked outputs into a consensus ranking: Average Rank computes mean rank per item; Borda assigns scores according to rank positions and sums them; Dowdall assigns reciprocal-weighted scores; Union collects top-k entries from each pipeline; Kemeny consensus is the formal optimal aggregation objective (minimizes pairwise disagreements) but is NP-hard to compute, so heuristics are used.</td>
                        </tr>
                        <tr>
                            <td><strong>system_type</strong></td>
                            <td>ensemble / rank-aggregation</td>
                        </tr>
                        <tr>
                            <td><strong>scientific_domain</strong></td>
                            <td>biology, medicine (applied to drug repurposing rankings)</td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_generation_method</strong></td>
                            <td>These methods do not themselves generate new hypotheses but combine hypotheses (ranked drug candidates) from multiple pipelines into a single prioritized list; the top-ranked items after aggregation are treated as hypotheses for experimental testing.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_assessment_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>plausibility_assessment_method</strong></td>
                            <td>Plausibility of aggregated hypotheses is empirically assessed by comparing aggregated top-K lists' hit rates against experimental (E918) and clinical (CT415) ground truth datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>novelty_plausibility_balance</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hypothesis_quality_metrics</strong></td>
                            <td>Quality assessed using AUC, precision@K, recall@K; Average Rank performed worst in this study, Borda and Dowdall had intermediate performance, and CRank (Bayesian-based) performed best overall.</td>
                        </tr>
                        <tr>
                            <td><strong>pre_experiment_evaluation</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>validation_mechanism</strong></td>
                            <td>Aggregated outputs validated against E918 experimental in vitro screening and CT415 clinical-trial snapshot; performance compared across aggregation methods and individual pipelines.</td>
                        </tr>
                        <tr>
                            <td><strong>reproducibility_measures</strong></td>
                            <td>All aggregation methods applied to the same frozen per-pipeline ranked lists (predictions frozen 2020-04-15), enabling reproducible aggregation outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_prevention_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_detection_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hallucination_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>statistical_significance_testing</strong></td>
                            <td>Empirical comparisons of aggregation methods are reported via AUC and precision/recall curves; statistical testing details for significance are referenced to SI but not enumerated in main text.</td>
                        </tr>
                        <tr>
                            <td><strong>uncertainty_quantification_method</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>benchmark_dataset</strong></td>
                            <td>E918, CT415, E74, CT615</td>
                        </tr>
                        <tr>
                            <td><strong>performance_metrics</strong></td>
                            <td>Average Rank performed worst overall; Borda had good performance on E918 but not CT415; Dowdall and Union performed better than Average Rank but generally trailed CRank; CRank (Bayesian) provided the most consistent high performance across datasets.</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_with_baseline</strong></td>
                            <td>Compared directly in figures (4G-H): CRank outperforms Average Rank, Borda (in some cases), Dowdall and Union; Union (taking top K/Np from each pipeline) sometimes yields good coverage but not as consistent as CRank.</td>
                        </tr>
                        <tr>
                            <td><strong>validated_on_real_science</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>novel_discoveries</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations</strong></td>
                            <td>Simple aggregation heuristics (Average Rank, Borda, Dowdall) may underperform when pipelines vary in quality or correlation; Kemeny consensus is theoretically optimal but NP-hard to compute exactly, necessitating heuristics.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Network medicine framework for identifying drug-repurposing opportunities for COVID-19', 'publication_date_yy_mm': '2020-04'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities <em>(Rating: 2)</em></li>
                <li>Prioritizing Network Communities <em>(Rating: 2)</em></li>
                <li>Going the Distance for Protein Function Prediction: A New Distance Metric for Protein Interaction Networks <em>(Rating: 2)</em></li>
                <li>Network-based in silico drug efficacy screening <em>(Rating: 2)</em></li>
                <li>Rank aggregation methods for the web <em>(Rating: 1)</em></li>
            </ol>
        </div>

        <div class="section">
            <h2>Extracted Data (Debug)</h2>
            <pre><code>{
    "id": "extraction-result-2651",
    "paper_id": "paper-836e965cd93369089027d31d92a55b5819cae267",
    "extraction_schema_id": "extraction-schema-68",
    "extracted_data": [
        {
            "name_short": "AI-based pipelines (A1-A4)",
            "name_full": "Artificial intelligence-based drug repurposing pipelines A1-A4",
            "brief_description": "A set of four AI-driven predictive pipelines that map drug protein targets and disease-associated proteins into a low-dimensional vector space (different drug-disease embeddings) to rank drugs by predicted efficacy against SARS-CoV-2.",
            "citation_title": "here",
            "mention_or_use": "use",
            "system_name": "AI-based embedding pipelines (A1-A4)",
            "system_description": "Maps drug protein targets and disease-associated proteins to points in a low-dimensional vector space (multiple embedding variants) and produces ranked lists of candidate drugs; implemented as four predictive pipelines (A1-A4) that rely on different drug-disease embeddings. The implementation in this paper treats each pipeline as a distinct embedding-based predictor and produces frozen ranked outputs (predictions saved as of 2020-04-15). The paper does not provide detailed architecture (e.g., exact embedding algorithm or neural network architecture) in the main text; it characterizes them as artificial intelligence / embedding-based methods producing drug-disease similarity scores and rankings.",
            "system_type": "graph-embedding / embedding-based (AI)",
            "scientific_domain": "biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)",
            "hypothesis_generation_method": "Generates hypotheses by ranking drugs according to similarity / proximity in the embedding space between drug targets and disease-associated proteins; top-ranked drugs constitute hypotheses of potential efficacy against SARS-CoV-2.",
            "novelty_assessment_method": null,
            "plausibility_assessment_method": "Implicit plausibility comes from proximity/similarity in learned embedding space and from downstream performance on ground-truth datasets (E918 experimental screen and CT415 clinical-trial list); no explicit internal plausibility scoring method beyond ranking is described in the main text.",
            "novelty_plausibility_balance": null,
            "hypothesis_quality_metrics": "Evaluated using standard ranking and classification metrics against ground truth: AUC (area under ROC), precision@K (number of positives among top K ranked drugs), recall@K (fraction of all positives appearing in top K). Specific reported values: AI pipelines achieved AUC=0.73-0.76 on CT415 (clinical-trial dataset), and various precision/recall results shown in figures.",
            "pre_experiment_evaluation": true,
            "validation_mechanism": "Computational ranking validated prospectively against two ground-truth datasets: (1) experimental in vitro screen of 918 drugs in VeroE6 cells (E918), classifying drugs Strong/Weak/No-effect/Cytotoxic; (2) a snapshot of drugs in clinical trials on 2020-04-15 (CT415). Performance metrics (AUC, precision/recall) quantify predictive performance prior to experimental follow-up.",
            "reproducibility_measures": "Predictions for all pipelines were produced using the same input data and frozen on a specific date (predictions saved on April 15, 2020) to maintain a prospective evaluation; the paper reports the exact drug lists and uses the same held-out experimental datasets (E918) for evaluation.",
            "hallucination_prevention_method": null,
            "hallucination_detection_method": null,
            "hallucination_rate": null,
            "statistical_significance_testing": "Authors report statistically significant predictive power across methods (see SI Section 3.1 and Tables S1-2), but the main text does not enumerate the specific statistical tests; details are referenced in the Supplementary Information.",
            "uncertainty_quantification_method": null,
            "benchmark_dataset": "E918 (experimental in vitro VeroE6 screen of 918 drugs), CT415 (clinical trials snapshot on 2020-04-15), additionally E74 (expert-curated prospective list) and CT615 (clinical trials refreshed on 2020-06-15) used elsewhere in SI.",
            "performance_metrics": "On CT415 (clinical-trial snapshot) AI pipelines achieved AUC in the range 0.73-0.76. For the experimental E918 dataset AI pipelines had lower AUCs (specific pipelines varied); precision@100 and recall@100 reported in figures (examples: A2 ranks 9 S&W drugs among top 100 in E918; A1 ranks 12 CT415 drugs among top 100). Exact numeric precision/recall curves are shown in Figure 4.",
            "comparison_with_baseline": "AI pipelines outperformed proximity methods on the CT415 clinical-trial dataset (AI AUC 0.73-0.76 vs proximity P1 AUC=0.57), but did not uniformly outperform other methods on the experimental E918 dataset; performance was dataset-dependent.",
            "validated_on_real_science": true,
            "novel_discoveries": "AI pipelines contributed to ranking drugs that later appeared in clinical trials and that matched experimental hits; specific top-ranked drugs by AI pipelines are included in the CRank consensus and experimental validation outcomes (see Tables).",
            "limitations": "The AI pipelines' predictive power is dataset-dependent (stronger for clinical-trial list than experimental in-vitro screen); main-text lacks low-level architectural detail of embeddings; no explicit internal uncertainty quantification or hallucination-detection mechanism described.",
            "uuid": "e2651.0",
            "source_info": {
                "paper_title": "Network medicine framework for identifying drug-repurposing opportunities for COVID-19",
                "publication_date_yy_mm": "2020-04"
            }
        },
        {
            "name_short": "Diffusion pipelines (D1-D5)",
            "name_full": "Network diffusion-based drug repurposing pipelines D1-D5",
            "brief_description": "Five diffusion-inspired pipelines that use network diffusion / diffusion state distance concepts to capture network similarity between drug targets and SARS-CoV-2 host protein targets to rank drug candidates.",
            "citation_title": "here",
            "mention_or_use": "use",
            "system_name": "Network diffusion pipelines (D1-D5)",
            "system_description": "Algorithms inspired by diffusion state distance: diffusion over the human protein-protein interaction network quantifies network similarity between drug target sets and SARS-CoV-2 host proteins; multiple pipelines (D1-D5) implement distinct statistical measures on diffusion-derived similarity scores to produce ranked drug lists.",
            "system_type": "network-diffusion / graph-signal-processing",
            "scientific_domain": "biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)",
            "hypothesis_generation_method": "Generates hypotheses by computing diffusion-based similarity/proximity between a drug's protein targets and the COVID-19 disease module in the interactome; drugs with high diffusion-based similarity are ranked highly as candidate therapeutics.",
            "novelty_assessment_method": null,
            "plausibility_assessment_method": "Plausibility is inferred from network proximity/diffusion metrics and validated by subsequent comparison to experimental (E918) and clinical (CT415) datasets; no other explicit plausibility scoring described.",
            "novelty_plausibility_balance": null,
            "hypothesis_quality_metrics": "Same evaluation metrics as other pipelines: AUC, precision@K, recall@K. Reported example: D2 achieved AUC=0.58 on the E918 experimental dataset.",
            "pre_experiment_evaluation": true,
            "validation_mechanism": "Prospective validation against the E918 in vitro screen and CT415 clinical trial snapshot using AUC, precision and recall metrics.",
            "reproducibility_measures": "Predictions frozen on April 15, 2020 and sharing same input interactome/disease-target data across pipelines; specific diffusion algorithmic details and parameters are described in the Supplementary Information (Section 1.4.2).",
            "hallucination_prevention_method": null,
            "hallucination_detection_method": null,
            "hallucination_rate": null,
            "statistical_significance_testing": "Predictive power and statistical significance are reported (see SI Section 3.1) though exact test names are not enumerated in main text.",
            "uncertainty_quantification_method": null,
            "benchmark_dataset": "E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot), additional datasets in SI.",
            "performance_metrics": "Example performance: D2 AUC = 0.58 on E918. Overall diffusion pipelines contributed to the set of predictions; different diffusion-based pipelines ranked different subsets of true positives.",
            "comparison_with_baseline": "Diffusion pipelines performed better than some methods for E918 (e.g., proximity performed well too), but did not uniformly outperform AI pipelines on CT415; methods are complementary (low correlation among pipeline rankings).",
            "validated_on_real_science": true,
            "novel_discoveries": null,
            "limitations": "Performance varies by ground-truth dataset; diffusion approaches capture network proximity but may miss non-network mechanisms; paper notes low correlation across different methods indicating complementary but inconsistent performance.",
            "uuid": "e2651.1",
            "source_info": {
                "paper_title": "Network medicine framework for identifying drug-repurposing opportunities for COVID-19",
                "publication_date_yy_mm": "2020-04"
            }
        },
        {
            "name_short": "Proximity pipelines (P1-P3)",
            "name_full": "Network proximity-based drug repurposing pipelines P1-P3",
            "brief_description": "Three proximity-based pipelines that rank drugs by shortest-path or distance measures between drug target proteins and SARS-CoV-2 host protein targets in the human interactome, with variants excluding drug carriers/metabolizers or using drug-induced gene expression.",
            "citation_title": "here",
            "mention_or_use": "use",
            "system_name": "Proximity-based pipelines (P1-P3)",
            "system_description": "Compute network-based proximity between drug target proteins and the COVID-19 disease module in the interactome; produce three variants: P1 uses all drug targets, P2 ignores targets flagged as carriers/transporters/metabolizing enzymes, and P3 relies on differentially expressed genes after drug exposure in cultured cells.",
            "system_type": "network-proximity / graph-distance-based",
            "scientific_domain": "biology, medicine (network medicine; drug repurposing for SARS-CoV-2/COVID-19)",
            "hypothesis_generation_method": "Generates hypotheses by ranking drugs whose targets are closest (in network distance) to the SARS-CoV-2 host-target disease module; closer proximity implies higher potential efficacy.",
            "novelty_assessment_method": null,
            "plausibility_assessment_method": "Plausibility inferred from network proximity Z-scores versus random expectation; the paper reports that targets of effective drugs are closer to the COVID-19 module than expected by chance.",
            "novelty_plausibility_balance": null,
            "hypothesis_quality_metrics": "AUC, precision@K, recall@K; example: P1 achieved AUC=0.63 on E918 (best single-pipeline AUC on the experimental dataset).",
            "pre_experiment_evaluation": true,
            "validation_mechanism": "Validated prospectively against E918 in vitro screening and CT415 clinical-trial snapshot; also network-based statistical comparisons to random expectation (proximity Z-scores).",
            "reproducibility_measures": "Predictions were computed using the same interactome and drug-target datasets and frozen on April 15, 2020; P3 predicts fewer drugs because it relies on drug-induced gene expression data.",
            "hallucination_prevention_method": null,
            "hallucination_detection_method": null,
            "hallucination_rate": null,
            "statistical_significance_testing": "Network proximity results are reported with Z-scores comparing to random expectation; broader statistical significance testing for predictive power referenced in SI (Section 3.1).",
            "uncertainty_quantification_method": null,
            "benchmark_dataset": "E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot).",
            "performance_metrics": "P1 AUC = 0.63 on E918 (best AUC on experimental dataset); P1 AUC = 0.57 on CT415, P2 AUC = 0.56 on CT415. Proximity measures (Z-scores) show S and W drug targets are significantly closer to COVID-19 module than N drugs (random expectation).",
            "comparison_with_baseline": "Proximity outperformed other methods on the experimental E918 dataset (P1 had highest single-pipeline AUC there), while AI pipelines performed better on the clinical-trial dataset; pipelines are complementary.",
            "validated_on_real_science": true,
            "novel_discoveries": null,
            "limitations": "P3 predicts fewer drugs owing to requirement for drug-induced expression data; proximity methods capture network-neighborhood effects but may fail to capture other mechanisms; overall variable performance across datasets.",
            "uuid": "e2651.2",
            "source_info": {
                "paper_title": "Network medicine framework for identifying drug-repurposing opportunities for COVID-19",
                "publication_date_yy_mm": "2020-04"
            }
        },
        {
            "name_short": "CRank",
            "name_full": "CRank rank aggregation algorithm (Bayesian factor-based Kemeny approximation)",
            "brief_description": "An unsupervised rank aggregation algorithm that uses Bayesian factors to approximate a Kemeny consensus across multiple predictive pipelines, producing a consensus ranking that consistently matches or exceeds individual pipeline performance.",
            "citation_title": "Prioritizing Network Communities",
            "mention_or_use": "use",
            "system_name": "CRank (Bayesian rank aggregation)",
            "system_description": "CRank is a heuristic rank aggregation algorithm that approximates the Kemeny consensus by leveraging Bayesian factors to weigh and combine multiple ranking lists; it seeks a ranking that maximizes pairwise agreements among pipelines and produces a consensus ranking used to prioritize candidate drugs.",
            "system_type": "ensemble / Bayesian rank-aggregation",
            "scientific_domain": "biology, medicine (drug repurposing; network medicine)",
            "hypothesis_generation_method": "Takes as input multiple hypothesis-producing pipelines (ranked drug lists) and produces an aggregated consensus ranking; hypotheses are the top-K drugs in the CRank consensus list.",
            "novelty_assessment_method": null,
            "plausibility_assessment_method": "Plausibility is assessed empirically by measuring the consensus ranking's hit rate against experimental and clinical ground truth datasets; CRank's Bayesian weighting favors consensus among diverse pipelines, which empirically increases plausibility of top-ranked hypotheses.",
            "novelty_plausibility_balance": null,
            "hypothesis_quality_metrics": "Evaluated using AUC, precision@K, recall@K; CRank achieved consistently high precision/recall across datasets. Specific metrics: CRank top-100 hit rate ~9% (order-of-magnitude higher than brute-force baseline 0.8%); top-800 of 6,340 drugs prioritized by CRank contained 58 of the 77 S&W experimental hits.",
            "pre_experiment_evaluation": true,
            "validation_mechanism": "Consensus predictions validated prospectively against the E918 in vitro screen and CT415 clinical-trial snapshot, and also tested on an expert-curated E74 prospective list and CT615 (clinical trials updated 06/15/20); CRank matched or exceeded best individual pipelines across these datasets.",
            "reproducibility_measures": "CRank aggregation was applied to the twelve frozen ranked lists (predictions frozen on 2020-04-15); experimental validation and manual curation steps are described and the aggregated ranked lists (top-100) are provided (Table 1), enabling reproducibility.",
            "hallucination_prevention_method": null,
            "hallucination_detection_method": null,
            "hallucination_rate": null,
            "statistical_significance_testing": "CRank's performance and significance reported across datasets (details in SI); the algorithm's success is justified empirically via comparisons of precision/recall and AUC versus individual pipelines and other aggregation heuristics.",
            "uncertainty_quantification_method": "Uses Bayesian factors as part of the aggregation process; Bayesian factors serve to weight evidence from different pipelines and implicitly capture inter-pipeline support (a form of uncertainty-weighted aggregation).",
            "benchmark_dataset": "E918 (experimental in vitro VeroE6 screen), CT415 (clinical trials snapshot 04/15/20), E74 (expert-curated), CT615 (06/15/20 refreshed clinical trials).",
            "performance_metrics": "CRank produced the best-consistent performance across datasets: top-100 hit rate ~9% (9 S&W drugs among CRank top-100); top-800 contained 58 of the 77 S&W drugs. CRank outperformed Average Rank and other simpler aggregation methods across most K values (Figure 4G-H).",
            "comparison_with_baseline": "CRank outperformed Average Rank (which performed worst), outperformed Union list and Dowdall in many settings, and matched/exceeded the best individual pipelines across datasets; CRank yielded ~9% top-100 hit rate versus brute-force screening baseline of 0.8%.",
            "validated_on_real_science": true,
            "novel_discoveries": "Using the CRank consensus and subsequent experimental screening, the study identified experimentally validated candidate drugs not widely in trials at the time (e.g., azelastine, digoxin) and highlighted several drugs with positive in vitro outcomes; these are presented as candidates for clinical consideration.",
            "limitations": "CRank depends on the quality and diversity of input pipelines; it aggregates existing predictions but does not generate fundamentally new mechanistic models; Bayesian factor details and priors are not fully elaborated in main text (some details are in referenced literature).",
            "uuid": "e2651.3",
            "source_info": {
                "paper_title": "Network medicine framework for identifying drug-repurposing opportunities for COVID-19",
                "publication_date_yy_mm": "2020-04"
            }
        },
        {
            "name_short": "Rank aggregation heuristics (Average Rank, Borda, Dowdall, Union, Kemeny)",
            "name_full": "Rank aggregation heuristics: Average Rank, Borda count, Dowdall method, Union-of-top-k, and Kemeny consensus (theoretical)",
            "brief_description": "A set of methods for combining multiple ranked lists into a single prioritized list: simple averaging of ranks, Borda count, the Dowdall method, selecting union of top-k lists, and the theoretical Kemeny consensus (NP-hard) as the optimal aggregation target.",
            "citation_title": "here",
            "mention_or_use": "use",
            "system_name": "Rank aggregation heuristics (Average Rank, Borda, Dowdall, Union, Kemeny)",
            "system_description": "Algorithms to aggregate multiple ranked outputs into a consensus ranking: Average Rank computes mean rank per item; Borda assigns scores according to rank positions and sums them; Dowdall assigns reciprocal-weighted scores; Union collects top-k entries from each pipeline; Kemeny consensus is the formal optimal aggregation objective (minimizes pairwise disagreements) but is NP-hard to compute, so heuristics are used.",
            "system_type": "ensemble / rank-aggregation",
            "scientific_domain": "biology, medicine (applied to drug repurposing rankings)",
            "hypothesis_generation_method": "These methods do not themselves generate new hypotheses but combine hypotheses (ranked drug candidates) from multiple pipelines into a single prioritized list; the top-ranked items after aggregation are treated as hypotheses for experimental testing.",
            "novelty_assessment_method": null,
            "plausibility_assessment_method": "Plausibility of aggregated hypotheses is empirically assessed by comparing aggregated top-K lists' hit rates against experimental (E918) and clinical (CT415) ground truth datasets.",
            "novelty_plausibility_balance": null,
            "hypothesis_quality_metrics": "Quality assessed using AUC, precision@K, recall@K; Average Rank performed worst in this study, Borda and Dowdall had intermediate performance, and CRank (Bayesian-based) performed best overall.",
            "pre_experiment_evaluation": true,
            "validation_mechanism": "Aggregated outputs validated against E918 experimental in vitro screening and CT415 clinical-trial snapshot; performance compared across aggregation methods and individual pipelines.",
            "reproducibility_measures": "All aggregation methods applied to the same frozen per-pipeline ranked lists (predictions frozen 2020-04-15), enabling reproducible aggregation outcomes.",
            "hallucination_prevention_method": null,
            "hallucination_detection_method": null,
            "hallucination_rate": null,
            "statistical_significance_testing": "Empirical comparisons of aggregation methods are reported via AUC and precision/recall curves; statistical testing details for significance are referenced to SI but not enumerated in main text.",
            "uncertainty_quantification_method": null,
            "benchmark_dataset": "E918, CT415, E74, CT615",
            "performance_metrics": "Average Rank performed worst overall; Borda had good performance on E918 but not CT415; Dowdall and Union performed better than Average Rank but generally trailed CRank; CRank (Bayesian) provided the most consistent high performance across datasets.",
            "comparison_with_baseline": "Compared directly in figures (4G-H): CRank outperforms Average Rank, Borda (in some cases), Dowdall and Union; Union (taking top K/Np from each pipeline) sometimes yields good coverage but not as consistent as CRank.",
            "validated_on_real_science": true,
            "novel_discoveries": null,
            "limitations": "Simple aggregation heuristics (Average Rank, Borda, Dowdall) may underperform when pipelines vary in quality or correlation; Kemeny consensus is theoretically optimal but NP-hard to compute exactly, necessitating heuristics.",
            "uuid": "e2651.4",
            "source_info": {
                "paper_title": "Network medicine framework for identifying drug-repurposing opportunities for COVID-19",
                "publication_date_yy_mm": "2020-04"
            }
        }
    ],
    "potentially_relevant_new_papers": [
        {
            "paper_title": "Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities",
            "rating": 2
        },
        {
            "paper_title": "Prioritizing Network Communities",
            "rating": 2
        },
        {
            "paper_title": "Going the Distance for Protein Function Prediction: A New Distance Metric for Protein Interaction Networks",
            "rating": 2
        },
        {
            "paper_title": "Network-based in silico drug efficacy screening",
            "rating": 2
        },
        {
            "paper_title": "Rank aggregation methods for the web",
            "rating": 1
        }
    ],
    "cost": 0.01699675,
    "model_str": "gpt-5-mini"
}</code></pre>
        </div>
        <div class="section">
            <h2>Paper</h2>
            <div class="paper-content"><h1>Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19</h1>
<p>Deisy Morselli Gysi ${ }^{1,2, <em>}$, Ãtalo Do Valle ${ }^{1, </em>}$, Marinka Zitnik ${ }^{3,4, <em>}$, Asher Ameli ${ }^{5,6, </em>}$, Xiao Gan ${ }^{1,2, <em>}$, Onur Varol ${ }^{1,7}$, Susan Dina Ghiassian ${ }^{5}$, JJ Patten ${ }^{8}$, Robert Davey ${ }^{8}$, Joseph Loscalzo ${ }^{9}$, and Albert-LÃ¡szlÃ³ BarabÃ¡si ${ }^{1,10}$<br>${ }^{1}$ Network Science Institute and Department of Physics, Northeastern University, Boston, MA 02115, USA; ${ }^{2}$ Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; ${ }^{3}$ Department of Biomedical Informatics, Harvard University, Boston, MA 02115, USA; ${ }^{4}$ Harvard Data Science Initiative, Harvard University, Cambridge, MA 02138, USA; ${ }^{5}$ Scipher Medicine, 221 Crescent St, Suite 103A, Waltham, MA 02453; ${ }^{6}$ Department of Physics, Northeastern University, Boston, MA 02115, USA; ${ }^{7}$ Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul 34956, Turkey; ${ }^{8}$ Department of microbiology, NEIDL, Boston University, Boston, MA, USA; ${ }^{9}$ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; ${ }^{10}$ Department of Network and Data Science, Central European University, Budapest 1051, Hungary. </em>Those authors contributed equally</p>
<h4>Abstract</h4>
<p>The current pandemic has highlighted the need for methodologies that can quickly and reliably prioritize clinically approved compounds for their potential effectiveness for SARS-CoV-2 infections. In the past decade, network medicine has developed and validated multiple predictive algorithms for drug repurposing, exploiting the sub-cellular network-based relationship between a drug's targets and disease genes. Here, we deployed algorithms relying on artificial intelligence, network diffusion, and network proximity, tasking each of them to rank 6,340 drugs for their expected efficacy against SARS-CoV-2. To test the predictions, we used as ground truth 918 drugs that had been experimentally screened in VeroE6 cells, and the list of drugs under clinical trial, that capture the medical community's assessment of drugs with potential COVID19 efficacy. We find that while most algorithms offer predictive power for these ground truth data, no single method offers consistently reliable outcomes across all datasets and metrics. This prompted us to develop a multimodal approach that fuses the predictions of all algorithms, showing that a consensus among the different predictive methods consistently exceeds the performance of the best individual pipelines. We find that 76 of the 77 drugs that successfully reduced viral infection do not bind the proteins targeted by SARS-CoV-2, indicating that these drugs rely on network-based actions that cannot be identified using docking-based strategies. These advances offer a methodological pathway to identify repurposable drugs for future pathogens and neglected diseases underserved by the costs and extended timeline of de novo drug development.</p>
<h1>Introduction</h1>
<p>The disruptive nature of the COVID-19 pandemic has unveiled the need for the rapid development, testing, and deployment of new drugs and cures. Given the compressed timescales, the de novo drug development process, that lasts a decade or longer, is not feasible. A time-efficient strategy must rely on drug repurposing (or repositioning), helping identify among the compounds approved for clinical use the few that may also have a therapeutic effect in patients with COVID-19. Yet, the lack of reliable repurposing methodologies has resulted in a winner-takes-all pattern, where more than one-third of registered clinical trials focus on hydroxychloroquine or chloroquine, siphoning away resources from testing a wider range of potentially effective drug candidates.</p>
<p>Drug repurposing algorithms rank drugs based on one or multiple streams of information, such as molecular profiles ${ }^{1}$, chemical structures ${ }^{2}$, adverse profiles ${ }^{3}$, molecular docking ${ }^{4}$, electronic health records ${ }^{5}$, pathway analysis ${ }^{6}$, genome wide association studies (GWAS) ${ }^{6}$, and network perturbations ${ }^{6-14}$. As typically only a small subset of the top candidates is validated experimentally, the true predictive power of the existing repurposing algorithms remains unknown. To quantify and compare their predictive power, different algorithms must make predictions for the same set of candidates, and the experimental validation must focus not only on the top candidates, but also on a wider list of drugs chosen independently of their predicted rank.</p>
<p>The COVID-19 pandemic presents both the societal imperative and the rationale to test drugs at a previously unseen scale. Hence, it offers a unique opportunity to quantify and improve the efficacy of the available predictive algorithms, while also identifying potential treatments for COVID-19. Here, we implement three recently developed network-medicine drug-repurposing algorithms that rely on artificial intelligence ${ }^{14,15}$, network diffusion ${ }^{16}$, and network proximity ${ }^{10}$ (Figure 1A, B). To test the validity of the predictions, we identified 918 drugs ranked by all predictive pipelines, that had been experimentally screened to inhibit viral infection and replication in cultured cells ${ }^{17}$. We also collected clinical trial data to capture the medical community's collective assessment of promising drug candidates. We find that the predictive power varies for the different datasets and metrics, indicating that in the absence of a priori ground truth, it is impossible to decide which algorithm to trust. We propose, however, a</p>
<p>multimodal ensemble forecasting approach that significantly improves the accuracy and the reliability of the predictions by seeking consensus among the predictive methods ${ }^{14,18}$.</p>
<h1>Network-based Drug Repurposing</h1>
<p>Repurposing strategies often prioritize drugs approved for (other) diseases whose molecular manifestations are similar to those caused by the pathogen or disease of interest ${ }^{19}$. To search for diseases whose molecular mechanisms overlap with the COVID-19 disease, we first mapped the experimentally identified ${ }^{20} 332$ host protein targets of the SARS-CoV-2 proteins (Table S4) to the human interactome ${ }^{21-24}$ (Table S3), a collection of 332,749 pairwise binding interactions between 18,508 human proteins (SI Section 1.1). We find that 208 of the 332 viral targets form a large connected component (COVID-19 disease module hereafter, Figure 2B), indicating that the SARS-CoV-2 targets aggregate in the same network vicinity ${ }^{12,25}$. Next, we evaluated the networkbased overlap between proteins associated with 299 diseases ${ }^{26}(d)$ and the host protein targets of SARS-CoV-2 (v) using the $S_{v d}$ metric ${ }^{26}$, finding $S_{v d}&gt;0$ for all diseases, implying that the COVID-19 disease module does not directly overlap with the disease proteins associated with any single disease (Figure S1-2 and Table S7). In other words, a potential COVID-19 treatment cannot be derived from the arsenal of therapies approved for a specific disease, arguing for a network-based strategy that can identify repurposable drugs without regard for their established disease indication.</p>
<p>We implemented three competing network repurposing methodologies (Figure 1B and SI Section 1.4): i) The artificial intelligence-based algorithm ${ }^{14,15}$ maps drug protein targets and diseaseassociated proteins to points in a low-dimensional vector space, resulting in four predictive pipelines A1-A4, that rely on different drug-disease embeddings. ii) The diffusion algorithm ${ }^{16}$ is inspired by diffusion state distance, and ranks drugs based on capturing network similarity of a drug's protein targets to the SARS-CoV-2 host protein targets. Powered by distinct statistical measures, the algorithm offers five ranking pipelines (D1-D5). iii) The proximity algorithm ${ }^{10}$ ranks drugs based on the distance between the host protein targets of SARS-CoV2 and the closest protein targets of drugs, resulting in three predictive pipelines of which P1 relies on all drug targets; P2 ignores targets identified as drug carriers, transporters, and drug-metabolizing enzymes; and P3 relies on differentially expressed genes identified by exposing each drug to</p>
<p>cultured cells ${ }^{27}$. The low correlations across the three algorithms indicate that the methods extract complementary information from the network (Figure 2C, and SI Section 1.5).</p>
<h1>Experimental and Clinical Validation of Drug Repurposing Pipelines</h1>
<p>We implemented the 12 pipelines to predict the expected efficacy of 6,340 drugs in Drugbank ${ }^{27}$ against SARS-CoV-2 and extracted and froze the predictions in the form of 12 ranked lists on April 15, 2020. All pipelines rely on the same input data and to maintain the prospective nature of the study, all subsequent analysis relies on this initial prediction list. As the different pipelines make successful predictions of a different subset of drugs, we identified 918 drugs for which all pipelines (except for P3, which predicts the smallest number of drugs) offer predictions and whose compounds were available in the Broad Institute drug repurposing library ${ }^{28}$ (Figure 1), and used two independent datasets to quantify the predictive power of each pipeline over the same set of drugs:
(1) As the first ground truth we used 918 compounds that had been experimentally screened for their efficacy against SARS-CoV-2 in VeroE6 cells, kidney epithelial cells derived from African green monkey ${ }^{17}$ (see SI Section 2). Briefly, the VeroE6 cells were pre-incubated with the drugs (from $8 \mu \mathrm{M}$ down to 8 nM ) and then challenged with wild type SARS-CoV-2 strain USA-WA1/2020. Of the 918 drugs, 806 had no detectable effect on viral infectivity ( N drugs, $87.8 \%$ of the tested list); 35 were cytotoxic to the host cells (C drugs); 37 had a strong effect (S drugs), being active over a broad range of concentrations; and 40 had a weak effect ( W drugs) on the virus (Figure 3A, Table S10). As the prediction pipelines offer no guidance on the magnitude of the in vivo effect, we consider as positive outcomes drugs that had a strong or a weak effect on the virus (S\&amp;W, 77 drugs, Table 2), and as negative outcomes the drugs without detectable effect (N, 806 drugs).
(2) On April 15, 2020 (prediction date), we scanned clinicaltrials.gov, identifying 67 drugs in 134 clinical trials for COVID-19 (CT415 dataset, Table S12). To compare outcomes across datasets, we limit our analysis to the experimentally tested 918 drugs, considering as positive the 37 drugs in clinical trial on the E918 list, and negative the remaining 881 drugs. As the outcomes of these trials are largely unknown, validation against CT415 dataset tests each pipeline's ability to predict the pharmacological consensus of the medical community on drugs with expected potential efficacy for COVID-19 patients.</p>
<p>For the E918 experimental outcomes (Figure 4A), the best area under the curve (AUC) of 0.63 is provided by P1, followed by D2 (AUC $=0.58$ ) and P3 (AUC $=0.58$ ). For CT415 (Figure 4B), we observe particularly strong predictive power for the four Al-based pipelines (AUC of 0.73-0.76), followed by proximity P1 (AUC $=0.57$ ) and P2 (AUC $=0.56$ ).</p>
<p>The goal of drug repurposing is to prioritize all available drugs, allowing the experimental efforts to limit their resources on the top-ranked ones. Thus, the most appropriate performance metric is the number of positive outcomes among top $K$ ranked drugs (precision at $K$ ), and the fraction of all positive outcomes among the top $K$ ranked drugs (recall at $K$ ). For the E918 dataset(Figure 4C) A2 ranks 9 S\&amp;W drugs among the top 100, followed by P1 (7 drugs) and A3 and A4 (6 drugs). We observe similar trends for recall (Figure 4E): the A2 pipeline ranks 11.7\% of all positive drugs in the top 100, and P1 selects 9\%. Finally, A1 ranks 12 drugs currently in clinical trials among the top 100 in CT415, followed by A3 (11 drugs) and A2 (10 drugs), trends that are similar for recall (Figure 4F).</p>
<p>Taken together, we find that while most algorithms show statistically significant predictive power (SI Section 3.1, Tables S1-2), they have different performance on the different ground truth datasets: the Al pipeline offers strong predictive power for the drugs selected for clinical trials, while proximity offers better predictive power for the E918 experimental outcomes. While together the twelve pipelines identify 22 positive drugs among the top 100, none of the pipelines offers consistent superior performance for all outcomes, prompting us to develop a multimodal approach that can extract the joint predictive power of all pipelines.</p>
<h1>Multimodal Approach for Drug Repurposing</h1>
<p>Predictive models for drug repurposing are driven by finite experimental resources that limit downstream experiments to those involving a finite number $(K)$ of drugs. How do we identify these $K$ drugs to maximize the positive outcomes of the tested list ${ }^{18}$ ? With no initial knowledge as to which of the $N_{p}=12$ predictive pipelines offer the best predictive power, we could place equal trust in all, by selecting the top $K / N_{p}$ drugs from each pipeline (Union list). We compare this scenario with an alternative strategy that combines the predictions of the different pipelines. A widely used approach is to calculate the average rank of each drug over the $N_{p}$ pipelines ${ }^{29}$ (Average Rank list). The alternative is to search for consensus ranking that maximizes the number of pairwise agreements between all pipelines ${ }^{15,18}$. As the optimal outcome, called the Kemeny</p>
<p>consensus ${ }^{29}$, is NP-hard to compute, we implemented three heuristic rank aggregation algorithms (RAAs) that approximate the Kemeny consensus: Borda's count ${ }^{30}$, the Dowdall method ${ }^{31}$, and CRank ${ }^{15}$. For example, if the resources allow us to test $K=120$ drugs, we ask which ranked list offers the best precision and recall at 120: the Union list collecting the top 10 predictions from the 12 pipelines; or the top 120 predictions of Average Rank, Borda, Dowdall, or CRank; or the top 120 drugs ranked by an individual pipeline.</p>
<p>We find that Average Rank offers the worst performance, trailing the predictive power of most individual pipelines (Figure 4G-H). The Union List and Dowdall offer better outcomes, but trail behind the best performing individual pipelines (E918, CT415). Borda has a strong predictive performance for E918, but not for CT415. In contrast, CRank, that relies on Bayesian factors, offers a consistently high predictive performance for all datasets and most $K$ values. CRank performs equally well for two other datasets: a manually curated prospective list E74 (described below) and the list of clinical trials updated on 06/15/20 (C615, Figure S8). In other words, we find that CRank extracts the cumulative predictive power of all methods, matching or exceeding the predictive power of the individual pipelines across all datasets. Its persistent performance indicates that an unsupervised multimodal approach can significantly improve the hit rate over individual prediction algorithms. It also suggests that in the absence of a ground truth, the Kemeny consensus, which seeks a ranking with the smallest number of pairwise disagreements between the individual pipelines, represents an effective and theoretically principled strategy when each pipeline carries some predictive power.</p>
<h1>Network Effects</h1>
<p>Most computationally informed drug repurposing methods rely on chemical binding energy minimization and docking patterns, limited to compounds that bind either to viral proteins or to the host targets of the viral proteins ${ }^{20}$ (Figure 1C). A good example is remdesivir, a direct-acting antiviral that inhibits viral RNA polymerase ${ }^{32,33}$. In contrast, our pipelines identify drugs that target host proteins to induce network-based perturbations that alter the virus's ability to enter the cell or to replicate within it. An example of such host-targeting drug ${ }^{34}$ is dexamethasone, which reduces mortality in COVID-19 patients by modulating the host immune system ${ }^{35}$. We find that only one of the 77 S\&amp;W drugs are known to directly target a viral protein binding target: amitriptyline, which targets SIGMAR1, the target of the NSP6 SARS-CoV-2 protein. In other words, 76 of the 77 drugs that show efficacy in our experimental screen are "network drugs",</p>
<p>achieving their effect indirectly, by perturbing the host subcellular network. As these drugs do not target viral proteins or their host targets target, they cannot be identified using traditional binding-based methods yet are successfully prioritized by network-based methods.</p>
<p>Searching for common mechanistic or structural patterns that could account for the efficacy of the 77 S\&amp;W drugs, we explored their target and pathway enrichment profiles (Figures S6-7), as well as their reported mechanisms of action, failing to identify statistically significant features shared by most S\&amp;W drugs. This failure is partly explained by the diversity of the S\&amp;W drugs (Table S10), containing antipsychotics (9S \&amp; 4W), serotonin receptor agonists (3W), non-steroidal anti-inflammatory drugs (2W), angiotensin receptor blockers (2W), tyrosine kinase inhibitors (5S), statins (1W \&amp; 2S), and others.</p>
<p>As CRank extracts its predictive power from the network, we hypothesized that network-based patterns may help distinguish the S\&amp;W drugs from the N drugs. Indeed, we find that the targets of the 37 S drugs form a statistically significant large connected component (Z-Score=2.05), indicating that these targets agglomerate in the same network neighborhood. We observe the same pattern for the targets of the 40 W drugs (Z-Score=3.42). The negative network separation between the S and W drug targets ( $\mathrm{S}_{\mathrm{SW}}=-0.69$ ) indicates that, in fact, the S and the W drugs target the same network neighborhood. To characterize this neighborhood, we measured the network-based proximity of the targets of the S, W, and N drug classes to the SARS-CoV-2 targets. We find that compared to random expectation, the N drug targets are far from the COVID-19 module (Figure 3C), while the S and W drug targets are closer to the COVID-19 disease module than expected by chance. The magnitude of the effect is also revealing: the $S$ drug targets are closer than the W drug targets, suggesting that network proximity is a positive predictor of a drug's efficacy.</p>
<p>Taken together, our analyses suggest that S\&amp;W drugs are diverse, and lack pathway-based or mechanistic signatures that distinguish them. We do find, however, that S\&amp;W drug target the same interactome neighborhood, located in the network vicinity of the COVID-19 disease module, potentially explaining their ability to influence viral activity, and the effectiveness of network-based methodologies to identify them.</p>
<h1>Discussion</h1>
<p>A recent in vitro screen ${ }^{36}$ of 12,000 compounds in VeroE6 cells identified 100 compounds that inhibit viral infectivity. Yet, only 2 of the 12,000 compounds tested are FDA approved, the rest being in the preclinical or experimental phase, years from reaching patients. In contrast, $96 \%$ of the 918 drugs prioritized and screened here are FDA approved, hence should they also show efficacy in human cell lines, could be moved immediately to rapid clinical trials. Brute force screening does, however, offer an important benchmark: Its low hit rate of $0.8 \%$ highlights the value in prioritizing resources towards the most promising compounds. Indeed, the unsupervised CRank offers an order of magnitude higher ( $9 \%$ ) hit rate among the top 100 drugs, and the top 800 of the 6,340 drugs prioritized by CRank contains 58 of the 77 S\&amp;W drugs (Figure 4G-H). The hit rate can be further increased by expert knowledge. To demonstrate this point, we mimicked the traditional drug repurposing process whereby a physician-scientist manually inspected the top 10\% of the CRank consensus ranking on April 15, removing drugs with known significant toxicities in vivo and lower-ranked members of the same drug class, and arrived at 74 drugs available for testing. Using the experimental design as described above, but over a wider range of doses ( $0.625-20 \mu \mathrm{M}, 0.2 \mathrm{MOI}$ ), we screened these 74 compounds separately from the E918 list, and found $39 \mathrm{~N}, 10 \mathrm{~W}$, and 11 S outcomes (Table S11). The resulting $28 \%$ enrichment of S\&amp;W drugs suggests that in the case of limited resources, outcomes are maximized by combining algorithmic consensus ranking with expert knowledge.</p>
<p>Inspecting the CRank list and the experimental outcomes, we find two highly ranked drugs with strong outcomes, but not yet in clinical trials (Table 1): azelastine (CRank #10, S), an antihistamine used to treat upper airway symptoms of allergies, and digoxin (CRank #33, S), used to treat heart failure. Our findings, coupled with extensive experience in their use in the clinical community, argue for their consideration in clinical trials. Other highly ranked candidates include folic acid (CRank #16, S), or methotrexate (CRank #32, S), which impairs folate metabolism and attenuates host inflammatory response in autoimmune diseases. This latter mechanism argues that methotrexate is likely to be effective at the other end of the disease spectrum, i.e., in the face of profound hyperimmune response to the infection. Omeprazole (CRank #50, S), used to suppress gastric acid production, alters lysosome acidification and, along with other benzimidazoles, binds to nonstructural protein 3 (nsp3). Blocking this protein, which enhances the virus's ability to evade the immune system ${ }^{37}$, was found to interfere in viral</p>
<p>formation of SARS-CoV-2 ${ }^{38}$. The combination of CRank and strong outcomes highlighted a few other drugs that may be considered for clinical trial based on knowledge of the general pharmacology, including fluvastatin (CRank #199, S), an HMG-CoA reductase inhibitor used to lower cholesterol, but with pleiotropic effects, including anti-inflammatory effects (likely a class effect, as atorvastatin and pitavastatin also had similar effects); ivermectin (CRank #235, S), an anti-parasitic agent; and sildenafil (CRank #493, S), a phosphodiesterase-5 inhibitor.</p>
<p>Taken together, the methodological advances presented here not only suggest potential drug candidates for COVID-19, but offer a principled algorithmic toolset to identify future treatments for diseases underserved by the cost and the timelines of conventional de novo drug discovery processes. As only 918 of the 6,340 drugs prioritized by CRank were screened, a selection driven by compound availability, many potentially efficacious FDA-approved drugs remain to be tested. Finally, it is also possible that some drugs that lacked activity in VeroE6 cells may nevertheless show efficacy in human cells, like loratadine (rank #95, N), which inhibited viral activity in the human cell line Caco-2 ${ }^{39}$. Ritonavir, our top-ranked drug, also showed no effect in our screen, despite the fact that over 42 clinical trials are exploring its potential efficacy in patients. In other words, some of the drugs ranked high by CRank may show efficacy, even if they are not among the 77 S\&amp;W drugs with positive outcomes.</p>
<h1>Authors Contribution</h1>
<p>A.A, D.M.G, M.Z, and X.G performed drug predictions. I.D.V analyzed disease comorbidities. R.D and J.J.P performed the drug experiments and the experimental screens. A.A, D.M.G, I.D.V, M.Z, O.V, X.G, and J.L analyzed the data. J.L manually curated the drug candidates. S.D.G guided A.A with designing diffusion-based similarity implementations. O.V curated list of drugs in clinical trials for COVID-19. A.L.B, D.M.G, I.D.V, and X.G wrote the paper with input from all authors. A.L.B designed the study. All authors read and approved the manuscript.</p>
<h2>Acknowledgments</h2>
<p>This work was supported, in part, by NIH grants HG007690, HL108630, and HL119145, and by American Heart Association grants D700382 and CV-19 to J.L; A.L.B is supported by NIH grant 1P01HL132825, American Heart Association grant 151708, and ERC grant 810115-DYNASET. M.Z. is supported, in part, by NSF grants IIS-2030459 and IIS-2033384, and by Harvard Data Science Initiative. J.J.P and R.A.D are supported by NIH grants PO1AI120943, RO1AI128364, RO1Ai125453 and from the Massachusetts Consortium on Pathogen Readiness. We wish to thank Nicolette Lee and Grecia Morales for providing support, Helia Sanchez for helping curate the list of drugs in clinical trials for COVID-19, Marc Santolini for suggestions in the diffusionbased methods and Raj S Dattani for comments on the manuscript.</p>
<h2>Declaration of interests</h2>
<p>J.L. and A.L.B are co-scientific founder of Scipher Medicine, Inc., which applies network medicine strategies to biomarker development and personalized drug selection. A.L.B is the founder of Nomix Inc. and Foodome, Inc. that apply data science to health; O.V and D.M.G are scientific consultants for Nomix Inc. I.D.V. is a scientific consultant for Foodome Inc.</p>
<p>Table 1. CRank Predictions for Drug Repurposing. Top 100 consensus predictions of the drug repurposing pipelines aggregated using the CRank algorithm. The top 100 drugs contain 9 drugs with positive experimental outcomes (S\&amp;W), 3 of which are among the top 10 drugs. Drugs highlighted in purple correspond to strong outcomes (S), in orange weak outcomes (W), in green to cytotoxic drugs, while non-highlighted drugs have shown no effect (N) in VeroE6 cells.</p>
<table>
<thead>
<tr>
<th style="text-align: center;">No-effect <br> Strong <br> Weak <br> Cytotoxic</th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: center;">CRank</td>
<td style="text-align: center;">Drug Name</td>
<td style="text-align: center;">CRank</td>
<td style="text-align: center;">Drug Name</td>
<td style="text-align: center;">CRank</td>
</tr>
<tr>
<td style="text-align: center;">1</td>
<td style="text-align: center;">Ritonavir</td>
<td style="text-align: center;">34</td>
<td style="text-align: center;">Gefitinib</td>
<td style="text-align: center;">67</td>
</tr>
<tr>
<td style="text-align: center;">2</td>
<td style="text-align: center;">Isoniazid</td>
<td style="text-align: center;">35</td>
<td style="text-align: center;">Enzalutamide</td>
<td style="text-align: center;">68</td>
</tr>
<tr>
<td style="text-align: center;">3</td>
<td style="text-align: center;">Troleandomycin</td>
<td style="text-align: center;">36</td>
<td style="text-align: center;">Theophylline</td>
<td style="text-align: center;">69</td>
</tr>
<tr>
<td style="text-align: center;">4</td>
<td style="text-align: center;">Cilostazol</td>
<td style="text-align: center;">37</td>
<td style="text-align: center;">Bicalutamide</td>
<td style="text-align: center;">70</td>
</tr>
<tr>
<td style="text-align: center;">5</td>
<td style="text-align: center;">Chloroquine</td>
<td style="text-align: center;">38</td>
<td style="text-align: center;">Trabectedin</td>
<td style="text-align: center;">71</td>
</tr>
<tr>
<td style="text-align: center;">6</td>
<td style="text-align: center;">Rifabutin</td>
<td style="text-align: center;">39</td>
<td style="text-align: center;">Nelfinavir</td>
<td style="text-align: center;">72</td>
</tr>
<tr>
<td style="text-align: center;">7</td>
<td style="text-align: center;">Flutamide</td>
<td style="text-align: center;">40</td>
<td style="text-align: center;">Beclomethasone dipropionate</td>
<td style="text-align: center;">73</td>
</tr>
<tr>
<td style="text-align: center;">8</td>
<td style="text-align: center;">Dexamethasone</td>
<td style="text-align: center;">41</td>
<td style="text-align: center;">Fluconazole</td>
<td style="text-align: center;">74</td>
</tr>
<tr>
<td style="text-align: center;">9</td>
<td style="text-align: center;">Rifaximin</td>
<td style="text-align: center;">42</td>
<td style="text-align: center;">Aminoglutethimide</td>
<td style="text-align: center;">75</td>
</tr>
<tr>
<td style="text-align: center;">10</td>
<td style="text-align: center;">Azelastine</td>
<td style="text-align: center;">43</td>
<td style="text-align: center;">Ifosfamide</td>
<td style="text-align: center;">76</td>
</tr>
<tr>
<td style="text-align: center;">11</td>
<td style="text-align: center;">Crizotinib</td>
<td style="text-align: center;">44</td>
<td style="text-align: center;">Hydroxychloroquine</td>
<td style="text-align: center;">77</td>
</tr>
<tr>
<td style="text-align: center;">12</td>
<td style="text-align: center;">Urea</td>
<td style="text-align: center;">45</td>
<td style="text-align: center;">Acetic acid</td>
<td style="text-align: center;">78</td>
</tr>
<tr>
<td style="text-align: center;">13</td>
<td style="text-align: center;">Methylprednisolone</td>
<td style="text-align: center;">46</td>
<td style="text-align: center;">Cyclophosphamide</td>
<td style="text-align: center;">79</td>
</tr>
<tr>
<td style="text-align: center;">14</td>
<td style="text-align: center;">Dimethyl sulfoxide</td>
<td style="text-align: center;">47</td>
<td style="text-align: center;">Methimazole</td>
<td style="text-align: center;">80</td>
</tr>
<tr>
<td style="text-align: center;">15</td>
<td style="text-align: center;">Cortisone acetate</td>
<td style="text-align: center;">48</td>
<td style="text-align: center;">Teniposide</td>
<td style="text-align: center;">81</td>
</tr>
<tr>
<td style="text-align: center;">16</td>
<td style="text-align: center;">Folic acid</td>
<td style="text-align: center;">49</td>
<td style="text-align: center;">Ribavirin</td>
<td style="text-align: center;">82</td>
</tr>
<tr>
<td style="text-align: center;">17</td>
<td style="text-align: center;">Celecoxib</td>
<td style="text-align: center;">50</td>
<td style="text-align: center;">Omeprazole</td>
<td style="text-align: center;">83</td>
</tr>
<tr>
<td style="text-align: center;">18</td>
<td style="text-align: center;">Betamethasone</td>
<td style="text-align: center;">51</td>
<td style="text-align: center;">Chlorambucil</td>
<td style="text-align: center;">84</td>
</tr>
<tr>
<td style="text-align: center;">19</td>
<td style="text-align: center;">Prednisolone</td>
<td style="text-align: center;">52</td>
<td style="text-align: center;">Citalopram</td>
<td style="text-align: center;">85</td>
</tr>
<tr>
<td style="text-align: center;">20</td>
<td style="text-align: center;">Mifepristone</td>
<td style="text-align: center;">53</td>
<td style="text-align: center;">Bortezomib</td>
<td style="text-align: center;">86</td>
</tr>
<tr>
<td style="text-align: center;">21</td>
<td style="text-align: center;">Budesonide</td>
<td style="text-align: center;">54</td>
<td style="text-align: center;">Leflunomide</td>
<td style="text-align: center;">87</td>
</tr>
<tr>
<td style="text-align: center;">22</td>
<td style="text-align: center;">Prednisone</td>
<td style="text-align: center;">55</td>
<td style="text-align: center;">Dimethyl fumarate</td>
<td style="text-align: center;">88</td>
</tr>
<tr>
<td style="text-align: center;">23</td>
<td style="text-align: center;">Oxiconazole</td>
<td style="text-align: center;">56</td>
<td style="text-align: center;">Teriflunomide</td>
<td style="text-align: center;">89</td>
</tr>
<tr>
<td style="text-align: center;">24</td>
<td style="text-align: center;">Megestrol acetate</td>
<td style="text-align: center;">57</td>
<td style="text-align: center;">Colchicine</td>
<td style="text-align: center;">90</td>
</tr>
<tr>
<td style="text-align: center;">25</td>
<td style="text-align: center;">Idelalisib</td>
<td style="text-align: center;">58</td>
<td style="text-align: center;">Phenylbutyric acid</td>
<td style="text-align: center;">91</td>
</tr>
<tr>
<td style="text-align: center;">26</td>
<td style="text-align: center;">Econazole</td>
<td style="text-align: center;">59</td>
<td style="text-align: center;">Progesterone</td>
<td style="text-align: center;">92</td>
</tr>
<tr>
<td style="text-align: center;">27</td>
<td style="text-align: center;">Rabeprazole</td>
<td style="text-align: center;">60</td>
<td style="text-align: center;">Triamcinolone</td>
<td style="text-align: center;">93</td>
</tr>
<tr>
<td style="text-align: center;">28</td>
<td style="text-align: center;">Quinine</td>
<td style="text-align: center;">61</td>
<td style="text-align: center;">Medroxyprogesterone acetate</td>
<td style="text-align: center;">94</td>
</tr>
<tr>
<td style="text-align: center;">29</td>
<td style="text-align: center;">Ticiopidine</td>
<td style="text-align: center;">62</td>
<td style="text-align: center;">Tioguanine</td>
<td style="text-align: center;">95</td>
</tr>
<tr>
<td style="text-align: center;">30</td>
<td style="text-align: center;">Hydrocortisone</td>
<td style="text-align: center;">63</td>
<td style="text-align: center;">Quercetin</td>
<td style="text-align: center;">96</td>
</tr>
<tr>
<td style="text-align: center;">31</td>
<td style="text-align: center;">Lansoprazole</td>
<td style="text-align: center;">64</td>
<td style="text-align: center;">Clobetasol</td>
<td style="text-align: center;">97</td>
</tr>
<tr>
<td style="text-align: center;">32</td>
<td style="text-align: center;">Methotrexate</td>
<td style="text-align: center;">65</td>
<td style="text-align: center;">Letrozole</td>
<td style="text-align: center;">98</td>
</tr>
<tr>
<td style="text-align: center;">33</td>
<td style="text-align: center;">Digoxin</td>
<td style="text-align: center;">66</td>
<td style="text-align: center;">Etoposide</td>
<td style="text-align: center;">99</td>
</tr>
<tr>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;">100</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th style="text-align: left;">CRank</th>
<th style="text-align: left;">Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: left;">34</td>
<td style="text-align: left;">Gefitinib</td>
</tr>
<tr>
<td style="text-align: left;">35</td>
<td style="text-align: left;">Enzalutamide</td>
</tr>
<tr>
<td style="text-align: left;">36</td>
<td style="text-align: left;">Theophylline</td>
</tr>
<tr>
<td style="text-align: left;">37</td>
<td style="text-align: left;">Bicalutamide</td>
</tr>
<tr>
<td style="text-align: left;">38</td>
<td style="text-align: left;">Trabectedin</td>
</tr>
<tr>
<td style="text-align: left;">39</td>
<td style="text-align: left;">Nelfinavir</td>
</tr>
<tr>
<td style="text-align: left;">40</td>
<td style="text-align: left;">Beclomethasone dipropionate</td>
</tr>
<tr>
<td style="text-align: left;">41</td>
<td style="text-align: left;">Fluconazole</td>
</tr>
<tr>
<td style="text-align: left;">42</td>
<td style="text-align: left;">Aminoglutethimide</td>
</tr>
<tr>
<td style="text-align: left;">43</td>
<td style="text-align: left;">Ifosfamide</td>
</tr>
<tr>
<td style="text-align: left;">44</td>
<td style="text-align: left;">Hydroxychloroquine</td>
</tr>
<tr>
<td style="text-align: left;">45</td>
<td style="text-align: left;">Acetic acid</td>
</tr>
<tr>
<td style="text-align: left;">46</td>
<td style="text-align: left;">Cyclophosphamide</td>
</tr>
<tr>
<td style="text-align: left;">47</td>
<td style="text-align: left;">Methimazole</td>
</tr>
<tr>
<td style="text-align: left;">48</td>
<td style="text-align: left;">Teniposide</td>
</tr>
<tr>
<td style="text-align: left;">49</td>
<td style="text-align: left;">Ribavirin</td>
</tr>
<tr>
<td style="text-align: left;">50</td>
<td style="text-align: left;">Omeprazole</td>
</tr>
<tr>
<td style="text-align: left;">51</td>
<td style="text-align: left;">Chlorambucil</td>
</tr>
<tr>
<td style="text-align: left;">52</td>
<td style="text-align: left;">Citalopram</td>
</tr>
<tr>
<td style="text-align: left;">53</td>
<td style="text-align: left;">Bortezomib</td>
</tr>
<tr>
<td style="text-align: left;">54</td>
<td style="text-align: left;">Leflunomide</td>
</tr>
<tr>
<td style="text-align: left;">55</td>
<td style="text-align: left;">Dimethyl fumarate</td>
</tr>
<tr>
<td style="text-align: left;">56</td>
<td style="text-align: left;">Teriflunomide</td>
</tr>
<tr>
<td style="text-align: left;">57</td>
<td style="text-align: left;">Colchicine</td>
</tr>
<tr>
<td style="text-align: left;">58</td>
<td style="text-align: left;">Phenylbutyric acid</td>
</tr>
<tr>
<td style="text-align: left;">59</td>
<td style="text-align: left;">Progesterone</td>
</tr>
<tr>
<td style="text-align: left;">60</td>
<td style="text-align: left;">Triamcinolone</td>
</tr>
<tr>
<td style="text-align: left;">61</td>
<td style="text-align: left;">Medroxyprogesterone acetate</td>
</tr>
<tr>
<td style="text-align: left;">62</td>
<td style="text-align: left;">Tioguanine</td>
</tr>
<tr>
<td style="text-align: left;">63</td>
<td style="text-align: left;">Quercetin</td>
</tr>
<tr>
<td style="text-align: left;">64</td>
<td style="text-align: left;">Clobetasol</td>
</tr>
<tr>
<td style="text-align: left;">65</td>
<td style="text-align: left;">Letrozole</td>
</tr>
<tr>
<td style="text-align: left;">66</td>
<td style="text-align: left;">Etoposide</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th style="text-align: left;">CRank</th>
<th style="text-align: left;">Drug Name</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: left;">67</td>
<td style="text-align: left;">Mebendazole</td>
</tr>
<tr>
<td style="text-align: left;">68</td>
<td style="text-align: left;">Adenosine</td>
</tr>
<tr>
<td style="text-align: left;">69</td>
<td style="text-align: left;">Mesalazine</td>
</tr>
<tr>
<td style="text-align: left;">70</td>
<td style="text-align: left;">Nevirapine</td>
</tr>
<tr>
<td style="text-align: left;">71</td>
<td style="text-align: left;">Belinostat</td>
</tr>
<tr>
<td style="text-align: left;">72</td>
<td style="text-align: left;">Mitomycin</td>
</tr>
<tr>
<td style="text-align: left;">73</td>
<td style="text-align: left;">Malathion</td>
</tr>
<tr>
<td style="text-align: left;">74</td>
<td style="text-align: left;">Ixekizumab</td>
</tr>
<tr>
<td style="text-align: left;">75</td>
<td style="text-align: left;">Vindesine</td>
</tr>
<tr>
<td style="text-align: left;">76</td>
<td style="text-align: left;">Secukinumab</td>
</tr>
<tr>
<td style="text-align: left;">77</td>
<td style="text-align: left;">Rifapentine</td>
</tr>
<tr>
<td style="text-align: left;">78</td>
<td style="text-align: left;">Bilastine</td>
</tr>
<tr>
<td style="text-align: left;">79</td>
<td style="text-align: left;">Clotrimazole</td>
</tr>
<tr>
<td style="text-align: left;">80</td>
<td style="text-align: left;">Erlotinib</td>
</tr>
<tr>
<td style="text-align: left;">81</td>
<td style="text-align: left;">Panobinostat</td>
</tr>
<tr>
<td style="text-align: left;">82</td>
<td style="text-align: left;">Warfarin</td>
</tr>
<tr>
<td style="text-align: left;">83</td>
<td style="text-align: left;">Busulfan</td>
</tr>
<tr>
<td style="text-align: left;">84</td>
<td style="text-align: left;">Goserelin</td>
</tr>
<tr>
<td style="text-align: left;">85</td>
<td style="text-align: left;">Hydroxyurea</td>
</tr>
<tr>
<td style="text-align: left;">86</td>
<td style="text-align: left;">Temsirolimus</td>
</tr>
<tr>
<td style="text-align: left;">87</td>
<td style="text-align: left;">Abiraterone</td>
</tr>
<tr>
<td style="text-align: left;">88</td>
<td style="text-align: left;">Miconazole</td>
</tr>
<tr>
<td style="text-align: left;">89</td>
<td style="text-align: left;">Ketorolac</td>
</tr>
<tr>
<td style="text-align: left;">90</td>
<td style="text-align: left;">Exemestane</td>
</tr>
<tr>
<td style="text-align: left;">91</td>
<td style="text-align: left;">Oxymetholone</td>
</tr>
<tr>
<td style="text-align: left;">92</td>
<td style="text-align: left;">Pentamidine</td>
</tr>
<tr>
<td style="text-align: left;">93</td>
<td style="text-align: left;">Diclofenac</td>
</tr>
<tr>
<td style="text-align: left;">94</td>
<td style="text-align: left;">Aminophylline</td>
</tr>
<tr>
<td style="text-align: left;">95</td>
<td style="text-align: left;">Loratadine</td>
</tr>
<tr>
<td style="text-align: left;">96</td>
<td style="text-align: left;">Fexofenadine</td>
</tr>
<tr>
<td style="text-align: left;">97</td>
<td style="text-align: left;">Terbinafine</td>
</tr>
<tr>
<td style="text-align: left;">98</td>
<td style="text-align: left;">Verapamil</td>
</tr>
<tr>
<td style="text-align: left;">99</td>
<td style="text-align: left;">Clopidogrel</td>
</tr>
<tr>
<td style="text-align: left;">100</td>
<td style="text-align: left;">Rivaroxaban</td>
</tr>
</tbody>
</table>
<p>Table 2 Drugs with Positive Experimental Outcomes. List of the 77 drugs with a positive outcome (S\&amp;W) from in vitro screen ${ }^{17}$. Drug response classification was obtained by a two-step model for drug response (see SI Section 2.3). Purple drugs show strong effect (S), and orange drugs showed weak effect (W).</p>
<table>
<thead>
<tr>
<th style="text-align: center;"></th>
<th style="text-align: center;">Strong <br> Weak</th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
<th style="text-align: center;"></th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
<td style="text-align: center;">Drug Name</td>
<td style="text-align: center;">CRank</td>
<td style="text-align: center;">Drug Name</td>
<td style="text-align: center;">CRank</td>
</tr>
<tr>
<td style="text-align: center;">5</td>
<td style="text-align: center;">Chloroquine</td>
<td style="text-align: center;">423</td>
<td style="text-align: center;">Pitavastatin</td>
<td style="text-align: center;">742</td>
<td style="text-align: center;">Mianserin</td>
</tr>
<tr>
<td style="text-align: center;">6</td>
<td style="text-align: center;">Rifabutin</td>
<td style="text-align: center;">431</td>
<td style="text-align: center;">Tenoxicam</td>
<td style="text-align: center;">755</td>
<td style="text-align: center;">Clofazimine</td>
</tr>
<tr>
<td style="text-align: center;">9</td>
<td style="text-align: center;">Rifaximin</td>
<td style="text-align: center;">438</td>
<td style="text-align: center;">Quinidine</td>
<td style="text-align: center;">767</td>
<td style="text-align: center;">Chlorpromazine</td>
</tr>
<tr>
<td style="text-align: center;">10</td>
<td style="text-align: center;">Azelastine</td>
<td style="text-align: center;">456</td>
<td style="text-align: center;">Sertraline</td>
<td style="text-align: center;">772</td>
<td style="text-align: center;">Imipramine</td>
</tr>
<tr>
<td style="text-align: center;">16</td>
<td style="text-align: center;">Folic acid</td>
<td style="text-align: center;">460</td>
<td style="text-align: center;">Ingenol mebutate</td>
<td style="text-align: center;">830</td>
<td style="text-align: center;">Promazine</td>
</tr>
<tr>
<td style="text-align: center;">32</td>
<td style="text-align: center;">Methotrexate</td>
<td style="text-align: center;">463</td>
<td style="text-align: center;">Norelgestromin</td>
<td style="text-align: center;">900</td>
<td style="text-align: center;">L-Alanine</td>
</tr>
<tr>
<td style="text-align: center;">33</td>
<td style="text-align: center;">Digoxin</td>
<td style="text-align: center;">493</td>
<td style="text-align: center;">Sildenafil</td>
<td style="text-align: center;">917</td>
<td style="text-align: center;">Moxifloxacin</td>
</tr>
<tr>
<td style="text-align: center;">44</td>
<td style="text-align: center;">Hydroxychloroquine</td>
<td style="text-align: center;">499</td>
<td style="text-align: center;">Eliglustat</td>
<td style="text-align: center;">933</td>
<td style="text-align: center;">Tasimelteon</td>
</tr>
<tr>
<td style="text-align: center;">50</td>
<td style="text-align: center;">Omeprazole</td>
<td style="text-align: center;">518</td>
<td style="text-align: center;">Ulipristal</td>
<td style="text-align: center;">995</td>
<td style="text-align: center;">Vandetanib</td>
</tr>
<tr>
<td style="text-align: center;">113</td>
<td style="text-align: center;">Clobetasol propionate</td>
<td style="text-align: center;">553</td>
<td style="text-align: center;">Cinacalcet</td>
<td style="text-align: center;">1000</td>
<td style="text-align: center;">Azilsartan medoxomil</td>
</tr>
<tr>
<td style="text-align: center;">118</td>
<td style="text-align: center;">Auranofin</td>
<td style="text-align: center;">556</td>
<td style="text-align: center;">Perphenazine</td>
<td style="text-align: center;">1020</td>
<td style="text-align: center;">Frovatriptan</td>
</tr>
<tr>
<td style="text-align: center;">120</td>
<td style="text-align: center;">Vinblastine</td>
<td style="text-align: center;">558</td>
<td style="text-align: center;">Idarubicin</td>
<td style="text-align: center;">1034</td>
<td style="text-align: center;">Zolmitriptan</td>
</tr>
<tr>
<td style="text-align: center;">199</td>
<td style="text-align: center;">Fluvastatin</td>
<td style="text-align: center;">564</td>
<td style="text-align: center;">Perhexiline</td>
<td style="text-align: center;">1035</td>
<td style="text-align: center;">Procarbazine</td>
</tr>
<tr>
<td style="text-align: center;">210</td>
<td style="text-align: center;">Clomifene</td>
<td style="text-align: center;">569</td>
<td style="text-align: center;">Amiodarone</td>
<td style="text-align: center;">1093</td>
<td style="text-align: center;">Asenapine</td>
</tr>
<tr>
<td style="text-align: center;">233</td>
<td style="text-align: center;">Ibuprofen</td>
<td style="text-align: center;">577</td>
<td style="text-align: center;">Duloxetine</td>
<td style="text-align: center;">1107</td>
<td style="text-align: center;">Dydonine</td>
</tr>
<tr>
<td style="text-align: center;">235</td>
<td style="text-align: center;">Ivermectin</td>
<td style="text-align: center;">585</td>
<td style="text-align: center;">Toremifene</td>
<td style="text-align: center;">1140.5</td>
<td style="text-align: center;">Clemastine</td>
</tr>
<tr>
<td style="text-align: center;">243</td>
<td style="text-align: center;">Atorvastatin</td>
<td style="text-align: center;">586</td>
<td style="text-align: center;">Afatinib</td>
<td style="text-align: center;">1194</td>
<td style="text-align: center;">Prochlorperazine</td>
</tr>
<tr>
<td style="text-align: center;">253</td>
<td style="text-align: center;">Pralatrexate</td>
<td style="text-align: center;">601</td>
<td style="text-align: center;">Amitriptyline</td>
<td style="text-align: center;">1222</td>
<td style="text-align: center;">Miglustat</td>
</tr>
<tr>
<td style="text-align: center;">263</td>
<td style="text-align: center;">Cobimetinib</td>
<td style="text-align: center;">626</td>
<td style="text-align: center;">Meclizine</td>
<td style="text-align: center;">1224</td>
<td style="text-align: center;">Prenylamine</td>
</tr>
<tr>
<td style="text-align: center;">269</td>
<td style="text-align: center;">Hydralazine</td>
<td style="text-align: center;">635</td>
<td style="text-align: center;">Valsartan</td>
<td style="text-align: center;">1276</td>
<td style="text-align: center;">Dalfampridine</td>
</tr>
<tr>
<td style="text-align: center;">297</td>
<td style="text-align: center;">Propranolol</td>
<td style="text-align: center;">651</td>
<td style="text-align: center;">Eletriptan</td>
<td style="text-align: center;">1314</td>
<td style="text-align: center;">Cinchocaine</td>
</tr>
<tr>
<td style="text-align: center;">317</td>
<td style="text-align: center;">Osimertinib</td>
<td style="text-align: center;">673</td>
<td style="text-align: center;">Sotalol</td>
<td style="text-align: center;">1355</td>
<td style="text-align: center;">Methotrimeprazine</td>
</tr>
<tr>
<td style="text-align: center;">348</td>
<td style="text-align: center;">Vincristine</td>
<td style="text-align: center;">678</td>
<td style="text-align: center;">Thioridazine</td>
<td style="text-align: center;">1396</td>
<td style="text-align: center;">Methylthioninium</td>
</tr>
<tr>
<td style="text-align: center;">367</td>
<td style="text-align: center;">Doxazosin</td>
<td style="text-align: center;">695</td>
<td style="text-align: center;">Chlorcyclizine</td>
<td style="text-align: center;">1403</td>
<td style="text-align: center;">Metixene</td>
</tr>
<tr>
<td style="text-align: center;">397</td>
<td style="text-align: center;">Rosiglitazone</td>
<td style="text-align: center;">707</td>
<td style="text-align: center;">Omacetaxine mepesuccinate</td>
<td style="text-align: center;">1443</td>
<td style="text-align: center;">Trifluoperazine</td>
</tr>
<tr>
<td style="text-align: center;">398</td>
<td style="text-align: center;">Aminolevulinic acid</td>
<td style="text-align: center;">721</td>
<td style="text-align: center;">Candesartan</td>
<td style="text-align: center;"></td>
<td style="text-align: center;"></td>
</tr>
</tbody>
</table>
<p><img alt="img-0.jpeg" src="img-0.jpeg" /></p>
<p>Figure 1 Network Medicine Framework for Drug Repurposing. (A) Study Design and Timeline. Following the publication of host-pathogen protein-protein interactions ${ }^{25}$ - March, $23^{\text {rd }}, 2020$ - we implemented three drug repurposing algorithms, relying on AI (A1-A4), network diffusion (D1-D5) and proximity (P1-P3), together resulting in 12 predictive ranking lists (pipelines, shown in (B)). Each pipeline offers predictions for a different number of drugs, what were frozen on April 15, 2020. We then identified 918 drugs for which all pipelines but P3 offered predictions, and experimentally validated their effect on the virus in VeroE6 cells ${ }^{17}$. The experimental (E918, E74) and clinical trial lists C415 offered the ground truth for validation and rank aggregation. (C) Direct target drugs bind either to a viral protein (D1) or to a host protein target of the viral proteins (D2). Network drugs (D3), in contrast, bind to the host proteins and limit viral activity by perturbing the host subcellular network.</p>
<p><img alt="img-1.jpeg" src="img-1.jpeg" /></p>
<p>Figure 2. COVID-19 Disease Module. (A) Proteins targeted by SARS-CoV-2 are not distributed randomly in the human interactome, but form a large connected component (LCC) consisting of 208 proteins, and multiple small subgraphs, shown in the figure. Almost all proteins in SARS-CoV-2 LCC are also expressed in the lung tissue, potentially explaining the effectiveness of the virus in causing pulmonary manifestations of the disease. (B) The random expectation of the LCC size indicates that the observed COVID-19 LCC, whose size is indicated by the red arrow, is larger than expected by chance (Z-score=1.65). (C) Heatmap of the Kendall $\tau$ statistic showing that the ranking list predicted by the different methods (A,D,P) are not correlated. We observe, however high correlations among the individual ranking list predicted by the same predictive method.</p>
<p><img alt="img-2.jpeg" src="img-2.jpeg" /></p>
<p>Figure 3 Experimental Outcomes and Network Origins. (A) Examples of dose-response curves for eight of the 918 experimentally validated drugs ${ }^{17}$, illustrating the four observed outcomes ( $\mathrm{S}, \mathrm{W}, \mathrm{C}$ and N ). VeroE6 cells were challenged in vitro with SARS-CoV-2 virus and treated with the drug over a range of doses (from 8 nM to $8 \mu \mathrm{M}$ ). A two-steps drug-response model (see SI Section 2.3) was used to classify each drug into Strong, Weak, Cytotoxic or No-Effect categories, according to their response to the drug in different doses and cell and viral reduction. (B) The sub-network formed by the targets of the 77 S\&amp;W drugs within the interactome. The link corresponds to binding interactions. Purple proteins are targeted by S drugs only; orange by W drugs only; proteins targeted by both S\&amp;W drugs are shown as pie charts, proportional to the number of targets in each category. (C) The targets of N drugs have a positive proximity Z-Score to the COVID-19 module, meaning they are further from the COVID-19 module than random expectation. By contrast, the targets of S\&amp;W drugs are more proximal (closer) to the COVID-19 module than expected by change, suggesting that their COVID-19 vicinity contribute to their ability to alter the virus's ability to infect the cells.</p>
<p><img alt="img-3.jpeg" src="img-3.jpeg" /></p>
<p>Figure 4 Performance of the Predictive Pipelines. (A,B) AUC (Area under the Curve), (C,D) Precision at 100, and (E,F) Recall at 100, for twelve pipelines tested for drug repurposing, each plot using as a gold standard the S\&amp;W drugs in E918 (left column) and drugs under clinical trials for treating COVID-19 as of April 15 ${ }^{\text {th }}, 2020$ (CT415, right column). (G,H) The top $\boldsymbol{K}$ precision and recall for the different rank aggregation methods (connected points), compared to the individual pipelines (empty symbols) documenting the consistent predictive performance of CRank. Similar results are shown for two other datasets in Figure S8: the prospective expert curated E74 and the clinical trial data refreshed on 06/15/20 (CT615)</p>
<h1>64 References</h1>
<ol>
<li>Dudley, J. T. et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease. Sci. Transl. Med. 3, 96ra76-96ra76 (2011).</li>
<li>Keiser, M. J. et al. Predicting new molecular targets for known drugs. Nature 462, 175181 (2009).</li>
<li>Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. \&amp; Bork, P. Drug target identification using side-effect similarity. Science 321, 263-266 (2008).</li>
<li>Dakshanamurthy, S. et al. Predicting New Indications for Approved Drugs Using a Proteochemometric Method. J. Med. Chem. 55, 6832-6848 (2012).</li>
<li>Paik, H. et al. Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. Sci. Rep. 5, 8580 (2015).</li>
<li>Greene, C. S. \&amp; Voight, B. F. Pathway and network-based strategies to translate genetic discoveries into effective therapies. Hum. Mol. Genet. 25, R94-R98 (2016).</li>
<li>Casas, A. I. et al. From single drug targets to synergistic network pharmacology in ischemic stroke. Proc. Natl. Acad. Sci. U. S. A. 116, 7129-7136 (2019).</li>
<li>Cheng, F. et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 9, 1-12 (2018).</li>
<li>Cheng, F., KovÃ¡cs, I. A. \&amp; BarabÃ¡si, A. L. Network-based prediction of drug combinations. Nat. Commun. 10, 1197 (2019).</li>
<li>Guney, E., Menche, J., Vidal, M. \&amp; BarÃ¡basi, A. L. Network-based in silico drug efficacy screening. Nat. Commun. 7, 10331 (2016).</li>
<li>
<p>Sadegh, S. et al. Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing. Nat. Commun. 11, 1-9 (2020).</p>
</li>
<li>
<p>Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 6, 1-18 (2020).</p>
</li>
<li>Zitnik, M., Agrawal, M. \&amp; Leskovec, J. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics 34, i457-i466 (2018).</li>
<li>Zitnik, M. et al. Machine Learning for Integrating Data in Biology and Medicine: Principles, Practice, and Opportunities. Inf. Fusion 50, 71-91 (2019).</li>
<li>Zitnik, M., Sosic, R. \&amp; Leskovec, J. Prioritizing Network Communities. Nat. Commun. 9, 2544 (2018).</li>
<li>Cao, M. et al. Going the Distance for Protein Function Prediction: A New Distance Metric for Protein Interaction Networks. PLoS One (2013). doi:10.1371/journal.pone.0076339</li>
<li>Patten, J. J. \&amp; et al. BU Drug Screening. Under Prep. (2020).</li>
<li>Guala, D. \&amp; Sonnhammer, E. L. A large-scale benchmark of gene prioritization methods. Sci. Rep. 7, 1-10 (2017).</li>
<li>Gulbahce, N. et al. Viral perturbations of host networks reflect disease etiology. PLoS Comput. Biol. 8, (2012).</li>
<li>Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 583, 459-468 (2020).</li>
<li>Luck, K., Sheynkman, G. M., Zhang, I. \&amp; Vidal, M. Proteome-Scale Human Interactomics. Trends in Biochemical Sciences 42, 342-354 (2017).</li>
<li>Caldera, M., Buphamalai, P., MÃ¼ller, F. \&amp; Menche, J. Interactome-based approaches to human disease. Curr. Opin. Syst. Biol. 3, 88-94 (2017).</li>
<li>
<p>Silverman, E. K. et al. Molecular networks in Network Medicine: Development and applications. Wiley Interdiscip. Rev. Syst. Biol. Med. e1489 (2020). doi:10.1002/wsbm. 1489</p>
</li>
<li>
<p>Buchanan, M., Caldarelli, G., De Los Rios, P., Rao, F. \&amp; Vendruscolo, M. Networks in Cell Biology. (Cambridge University Press, 2010). doi:10.1017/CBO9780511845086</p>
</li>
<li>Gulbahce, N. et al. Viral perturbations of host networks reflect disease etiology. PLoS Comput. Biol. 8, 1002531 (2012).</li>
<li>Menche, J. et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science 347, 1257601 (2015).</li>
<li>Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46, D1074-D1082 (2018).</li>
<li>Corsello, S. M. et al. The Drug Repurposing Hub: a next-generation drug library and information resource. Nat. Med. 23, 405-408 (2017).</li>
<li>Dwork, C., Kumar, R., Naor, M. \&amp; Sivakumar, D. Rank aggregation methods for the web. in Proceedings of the 10th International Conference on World Wide Web, WWW 2001 613622 (Association for Computing Machinery, Inc, 2001). doi:10.1145/371920.372165</li>
<li>Borda, J. C. Memoire sur les elections au scrutin. MÃ©moires de l'acadÃ©mie royale 657664 (1781).</li>
<li>Reilly, B. Social choice in the south seas: Electoral innovation and the Borda count in the Pacific Island countries. Int. Polit. Sci. Rev. (2002). doi:10.1177/0192512102023004002</li>
<li>Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269-271 (2020).</li>
<li>Beigel, J. H. et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N. Engl. J. Med. NEJMoa2007764 (2020). doi:10.1056/NEJMoa2007764</li>
<li>Lin, K. \&amp; Gallay, P. Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Res. 99, 68-77 (2013).</li>
<li>
<p>Horby, P. et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv (2020). doi:10.1101/2020.06.22.20137273</p>
</li>
<li>
<p>Riva, L. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 1-11 (2020). doi:10.1038/s41586-020-2577-1</p>
</li>
<li>Virdi, R. S., Bavisotto, R. V., Hopper, N. C. \&amp; Frick, D. N. Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3. bioRxiv 2020.07.06.190413 (2020). doi:10.1101/2020.07.06.190413</li>
<li>Aguila, E. J. T. \&amp; Cua, I. H. Y. Repurposed GI Drugs in the Treatment of COVID-19. Dig. Dis. Sci. 1, 1-2 (2020).</li>
<li>Ellinger, B. et al. Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection. Res. Sq. 1-19 (2020). doi:10.21203/RS.3.RS-23951/V1</li>
</ol>
<h1>Supplementary Information: Network Medicine Framework for Identifying Drug Repurposing Opportunities for COVID-19</h1>
<p>Deisy Morselli Gysi, Ãtalo Do Valle, Marinka Zitnik, Asher Ameli, Xiao Gan, Onur Varol, Susan Dina Ghiassian, JJ Patten, Robert Davey, Joseph Loscalzo, and Albert-LÃ¡szlÃ³ BarabÃ¡si</p>
<h2>Table of Contents</h2>
<p>1 Network-Based Drug Repurposing For COVID-19 ..... 2
1.1 Human Interactome and SARS-CoV-2 and Drug Targets ..... 2
1.2 Lung Gene Expression (Fig 2A) ..... 3
1.3 Disease Comorbidities ..... 3
1.4 Drug Repurposing Prediction Algorithms ..... 7
1.4.1 Artificial Intelligence Based Algorithm (A1-A4) ..... 7
1.4.2 Diffusion-Based Algorithms (D1-D5) ..... 10
1.4.3 Proximity Algorithm (P1-P3) ..... 12
1.5 Network Properties of Prediction Algorithms ..... 13
1.5.1 Explanatory Subgraphs ..... 13
1.5.2 Complementarity of Prediction Algorithms (Fig 2C) ..... 16
2 Experimental Validation ..... 18
2.1 Cell Cultivation and Viruses Used ..... 18
2.2 Virus Infection Inhibition Assay ..... 18
2.3 Drug-Response Classification ..... 19
2.4 Biological Interpretation of Effective Drugs in E918 Dataset ..... 19</p>            </div>
        </div>

    </div>
</body>
</html>